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CHAPTER I 
INTRODUCTION 
ORAL CONTROLLED DRUG DELIVERY SYSTEMS 
 
Oral drug delivery systems 
 The most preferred route of drug administration for systemic delivery of 
drugs is oral route. More than 50% of drug delivery systems available in the market 
are oral drug delivery systems. These systems have the obvious advantages of case of 
administration and patient acceptance. One would always like to have ideal drug 
delivery systems that will possess two main properties,  
1. It will be a single dose for the whole duration of treatment,  
2. It will deliver the active drug directly at the site of action.  
 
 It offers advantages like, 
 Ease of administration 
 Patient compliance 
 Flexibility in formulation(“Novel drug delivery systems” by Chein Y.W, 
1982, 2
nd
edition) 
 
The controlled drug release 
 Controlled drug delivery is one which delivers the drug at a predetermined 
rate, for locally or systemically, for a specified period of time. 
 Continuous oral delivery of drugs at predictable & reproducible kinetics for 
predetermined period throughout the course of GIT. 
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                                                  FIGURE 1 
 
Oral Controlled Release Formulation 
 Oral route has been the commonly selected and most convenient for the drug 
delivery.  
Most of the oral controlled drug delivery systems rely on diffusion, dissolution or 
combination of both mechanisms, to release the drug in a controlled manner to the 
Gastrointestinal Tract (GIT).  
 Targeting systems are either releasing drug in controlled manner or in one 
burst at the specific area.(“Targeted and controlled drug delivery” by Vyas S.P., 
Khar R K ) The goal of a targeted oral drug delivery system (TODDS) is to achieve 
better therapeutics success compared to conventional dosage form. This can be 
achieved by improving the pharmacokinetic profile, patient convenience and 
compliance in therapy, some of the advantages of TODDS are: 
 Reduced dosing frequency 
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 Better patient convenience and compliance 
 Reduced GI side effects and other toxic effects. 
 Less fluctuating plasma drug level 
 More uniform drug effect 
 Less total dose 
 Better stability of the drug. 
 
On the other hand TODDS suffer from a number of potential disadvantages: 
 Higher cost 
 Relatively poor in vitro-in vivo correlation 
 Possible dose dumping  
 Reduced potential for dose change or withdrawal in the event of toxicity 
 Targeting of drugs through oral route involves control of time of release or 
location of release. On the basis of environmental, anatomical and physiological 
factors these drug delivery system can be classified with respect to target site as 
follows: 
 Systems targeted to stomach/duodenum 
 Systems targeted to small intestine 
 Systems targeted to large intestine/colon 
 Systems targeted to lymphatic. 
Factors influencing the design and performance of controlled drug 
deliverysystem 
Biopharmaceutics characteristics of drug 
 Molecular weight of the drug  
 Aqueous solubility of the drug  
 Apparent partition coefficient  
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 Drug pKa and ionization physiological pH 
 Drug stability  
 Mechanism and site of absorption  
 Route of administration. 
Pharmacokinetic characteristic of the drug  
 Absorption rate  
 Elimination half life  
 Rate of metabolism  
 Dosage form index  
Pharmacodynamic characteristic of the drug  
 Therapeutic range  
 therapeutic index  
 Plasma–concentration–response relationship. 
Advantages of controlled drug delivery systems 
 Improved patient convenience and compliance  
 Reduction in fluctuation in steady state levels. 
 Increased safety margin of high potency drugs. 
 Reduction in dose. 
 Reduction in health care cost. 
 Total dose is low. 
 Reduced GI side effects. 
 Better patient acceptance and compliance.  
 Less fluctuation at plasma drug levels.  
 More uniform drug effect  
 Improved efficacy/safety ratio. 
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 Dose dumping.   
 Reduced potential for accurate dose adjustment. 
 Need of additional patient education. 
 Reduced dosing frequency. 
Disadvantages of controlled drug delivery systems  
 Decreased systemic availability. 
 Poor invitro-invivo correlations. 
 Chances of dose dumping. 
 Dose withdrawal is not possible. 
 Higher cost of formulation. 
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CHAPTER II 
BUCCAL DRUG DELIVERY SYSTEM - A REVIEW 
Buccal route of drug delivery is a good alternative, amongst the various 
routes of drug delivery. Oral route is perhaps the most preferred for the patients. 
Within the oral mucosal cavity, the buccal region offers an attractive route of 
administration for systemic drug delivery. However, oral administration of drugs has 
disadvantages such as hepatic first pass metabolism and enzymatic degradation 
within the GI tract, that prohibit oral administration of certain classes of drugs 
especially peptides and proteins.  
Buccal drug delivery offer distinct advantages over oral administration for 
systemic drug delivery. These advantages include possible bypass of first pass effect, 
avoidance of pre-systemic elimination within the GI tract, these factors make the oral 
mucosal cavity a very attractive and feasible site for systemic drug delivery. 
Considering the low patient compliance of rectal, vaginal, sublingual and nasal drug 
delivery for controlled release, the buccal mucosa has rich blood supply and it is 
relatively permeable.  
The buccal mucosa lines the inner cheek and buccal formulations are placed 
in the mouth between the upper gingival (gums) and cheek to treat local and systemic 
conditions. (Pankil A. Gandhi et al., 2011) 
ADVANTAGES OF BUCCAL DRUG DELIVERY 
 Bypass the gastrointestinal tract and hepatic portal system, increasing the   
bioavailability of orally administered drugs that otherwise undergo hepatic 
first-pass metabolism. 
 Improved patient compliance due to the elimination of associated pain with 
injections. 
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 Sustained drug delivery. 
 A relatively rapid onset of action can be achieved relative to the oral route 
and the formulation can be removed if therapy is required to be discontinued. 
 Increased ease of drug administration 
 The large contact surface of the oral cavity contributes to rapid and extensive 
drug absorption 
 Extent of perfusion is more therefore quick and effective absorption. 
 Nausea and vomiting are greatly avoided. 
 Used in case of unconscious and less cooperative patients. 
 Drugs, which show poor bioavailability via the oral route, can be 
administered conveniently. 
Eg: Drugs, which are unstable in the acidic environment of the stomach or are 
destroyed by the enzymatic or alkaline environment of the intestine. 
LIMITATIONS OF BUCCAL DRUG DELIVERY: 
 Drugs which irritate oral mucosa or have bitter taste, or cause allergic 
reactions, discoloration of teeth cannot be formulated. 
 If formulation contains antimicrobial agents, affects the natural microbes in 
the buccal cavity. 
 The patient cannot eat/drink/speak. 
 Only those drugs which are absorbed by passive diffusion can be 
administered by this route. 
 Drugs which are unstable at buccal pH cannot be administered by this route. 
 Swallowing of saliva can also potentially lead to the loss of dissolved or 
suspended drug 
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 Low permeability of the buccal membrane, specifically when compared to the 
sublingual membrane. (Pankil A. Gandhi et al., 2011) 
OVERVIEW OF BUCCAL MUCOSA 
A. Structure 
 
                     FIGURE 2: CROSS SECTION OF ORAL MUCOSA 
The oral mucosa is anatomically divided into 
1) Epithelium 
2) Basement membrane and Connective tissues 
1) Epithelium:  
The epithelium consists of approximately 40–50 layers of stratified squamous 
epithelial cells having thickness 500-800μm. The epithelium of the oral mucosa 
serves as a protective covering for the tissues and a barrier to the entry of foreign 
materials. These functions are reflected in the organization of the epithelium in 
which individual epithelial cells are closely opposed and stratified so there are a 
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number of layers that show a sequence of differentiation. The uppermost layers form 
a surface that is resistant to physical insult and to penetration by foreign substances. 
Membrane Coating Granules (MCG) are spherical or oval organelles (100–300 nm in 
diameter). (Pankil A. Gandhi et al., 2011) 
2) Basement Membrane and Connective Tissue  
The basement membrane (BM) is a continuous layer of extracellular 
materials and forms a boundary between the basal layer of epithelium and the 
connective tissues. This basal complex anchors the epithelium to the connective 
tissue and supplements the barrier function of the superficial layers of the epithelium 
to prevent some large molecules from passing the oral mucosa. The bulk of 
connective tissue consists of a collagen fiber network, the organization of which 
determines mechanical stability, resistance to deformation, and extendibility of the 
tissue. (Pankil A. Gandhi et al., 2011)  
Permeability:- 
It is estimated that the permeability of the buccal mucosa is 4-4000 times 
greater than the skin. There are considerable differences in permeability between 
different region of the oral cavity because of diverse structures and functions of the 
different oral mucosa. In general, the permeability of the oral mucosa decreases in 
the order of sublingual greater than buccal, and buccal greater than palatal. This rank 
order is based on the relative thickness and degree of keratinization of these tissues, 
with the sublingual mucosa being relatively thin and non-keratinized, the buccal 
thicker and non-keratinized, and the palatal intermediate in thickness but keratinized. 
In buccal mucosa two routes of passive transport are found one involves the transport 
of compounds through the intercellular space between the cells (paracellular) and 
other involves passage into and across the cells (transcellular). 
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B. Environment  
The oral cavity is marked by the presence of saliva produced by the salivary 
glands and mucus which is secreted by the major and minor salivary glands as part of 
saliva. (Santanu Roychowdhury et al., 2011) 
The mucus layer 
Mucus is a translucent and viscid secretion which forms a thin, continuous 
gel blanket adherent to the mucosal epithelial surface. The mean thickness of this 
layer varies from about 50 to 450 m in humans. It is secreted by the goblet cells 
lining the epithelia or by special exocrine glands with mucus cells. 
Functions of mucus layer 
The Primary functions of the mucus layer are: 
i. Protective: Resulting particularly from its hydrophobicity and protecting the 
mucosa from the diffusion of hydrochloric acid from the lumen to the 
epithelial surface. 
ii. Barrier: The role of the mucus layer as a barrier in tissue absorption of drugs 
and other substrates is well known as it influences the bioavailability of drug. 
iii. Adhesion: Mucus has strong cohesional properties and firmly binds to the 
epithelial cell surface as a continuous gel layer. 
iv. Lubrication: An important role of the mucus layer is to keep the mucosal 
membrane moist. 
PHYSIOLOGICAL FACTORS AFFECTING BUCCAL BIOAVAILABILITY 
1. Inherent permeability of the epithelium Thickness of epithelium 
2. Blood supply 
3. Metabolic activity 
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4. Saliva and mucus 
5. Ability to retain delivery system 
6. Species differences 
7. Transport routes and mechanisms (Gupta S.K et al., 2011) 
BUCCAL ROUTES OF DRUG ABSORPTION 
There are two permeation pathways for passive drug transport across the oral 
mucosa:  
 Paracellular routes  
 Transcellular routes.  
Permeants can use these two routes simultaneously, but one route is usually 
preferred over the other depending on the physicochemical properties of the 
diffusant. Since the intercellular spaces and cytoplasm are hydrophilic in character, 
lipophilic compounds would have low solubilities in this environment. The cell 
membrane, however, is rather lipophilic in nature and hydrophilic solutes will have 
difficulty permeating through the cell membrane due to a squat partition coefficient. 
Therefore, the intercellular spaces pose as the main barrier to permeation of 
lipophilic compounds and the cell membrane acts as the major transport barrier for 
hydrophilic compounds.  
THEORIES OF MUCOADHESION: 
Several theories have been put forward to explain the mechanism of 
polymer–mucus interactions that lead to mucoadhesion. To start with, the sequential 
events that occur during bioadhesion include an intimate contact between the 
bioadhesive polymer and the biological tissue due to proper wetting of the 
bioadhesive surface and swelling of the bioadhesive.  
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1.Electronic Theory:  
The adhesive polymer and mucus typically have different electronic 
characteristics. When these two surfaces come in contact, a double layer of electrical 
charge forms at the interface, and then adhesion develops due to the attractive force 
from electron transfer across the electrical double layer.  
2. Adsorption Theory:  
The adsorption theory of bioadhesion proposes that adhesion of a polymer to 
a biological tissue results from: 
 (i) primary chemical bonds that are somewhat permanent and therefore undesirable 
in bioadhesion  
(ii) van der Waals, hydrogen, hydrophobic and electrostatic forces, which form 
secondary chemical bonds.  
3. Wetting Theory:  
Primary application to liquid bioadhesive system, the wetting theory 
emphasizes the intimate contact between the adhesive and mucus. Thus, a wetting 
surface is controlled by structural similarity, degree of cross linking of the adhesive 
polymer, or use of a surfactant.  
The work of adhesion [expressed in terms of surface and interfacial tension (Y) being 
defined as energy per cm2 released when an interface is formed.]  
According to Dupres equation work of adhesion is given by 
                                               Wa = YA + YB – YAB  
Where,  
A & B refer to the biological membranes and the bioadhesive formulation 
respectively. 
 The work of cohesion is given by:  
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                                                           Wc = 2YA or YB  
For a bioadhesive material B spreading on a biological substrate, the 
spreading coefficient is given by: 
                                                          SB/A = YA – (YB+YAB)  
SB/A should be positive for a bioadhesive material to adhere to a biological 
membrane. 
 4. Diffusion Theory:  
The essence of this theory is that chains of the adhesive and the substrate 
interpenetrate one another to a sufficient depth to create a semi permanent adhesive 
bond. The penetration rate depends on the diffusion coefficient of both interacting 
polymers, and the diffusion co-efficient is known to depend on molecular weight and 
cross-linking density. In addition, segment mobility, flexibility of the bioadhesive 
polymer, mucus glycoprotein, and the expanded nature of both network are important 
parameters that need to be considered. 
 5.Fracture:  
Fracture theory of adhesion is related to separation of two surfaces after 
adhesion. The fracture strength is equivalent to adhesive strength as given by  
G = (Eε. /L) ½  
Where, 
E- Young’s modules of elasticity  
ε- Fracture energy 
L- Critical crack length when two surfaces are separated. (Anay R. Patel et 
al., 2011) 
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BUCCAL FORMULATIONS: 
 The size of the delivery system varies with the type of formulation, i.e., a 
buccal tablet may be approximately 5–8mm in diameter, whereas a flexible 
buccal patch may be as large as 10–15cm2 in area. 
 Mucoadhesive buccal patches with a surface area of 1–3 cm2 are most 
acceptable. 
 It has been estimated that the total amount of drug that can be delivered 
across the buccal mucosa from a 2-cm2 system in 1 day is approximately 10–
20 mg. 
 The shape of the delivery system may also vary, although for buccal drug 
administration, an ellipsoid shape appears to be most acceptable. 
 The thickness of the delivery device is usually restricted to only a few 
millimeters. 
 The location of the delivery device also needs to be considered 
 The maximal duration of buccal drug retention and absorption is 
approximately 4– 6 h because food and/or liquid intake may require removal 
of the delivery device. 
 Physiology of mucus membrane under disease condition need to be 
accounted for (e.g.: Cancer patients suffer from oral candidosis) 
BUCCAL TABLETS: 
Buccal tablets are dry solid dosage forms that may have to be placed in the 
buccal mucosa. The size of the tablet is restricted to that which can be comfortably 
retained in place for prolonged periods.  
 Buccal adhesive tablets are held between the gum and cheek. 
 Generally flat, elliptical or capsule-shaped. 
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 Troches & lozenges are two other types of tablets used in oral cavity where 
they are intended to exert a local effect in the mouth or throat. 
 Buccoadhesive tablet may be monolithic or bilaminated system. 
 Monolithic is multidirectional release 
 Bilayered containing core layer & backing layer. 
 Backing layer may be of water insoluble material like Ethyl cellulose or 
hydrogenated castor oil or may be polymeric coating layer 
 Backing layer avoids sticking of the tablet to the finger during application. 
(Pankil A. Gandhi et al., 2011) 
Limitations of buccal tablets 
 The small surface of contact with mucosa. 
 Their lack of physical flexibility.It is difficult to get high release rate, which 
is required for some drugs. 
 The extent and frequency of contact may cause irritation following chronic 
application of the buccal mucosa. (Pankil A. Gandhi et al., 2011) 
BIOADHESIVE POLYMERS: 
  Bioadhesive polymers have properties to get adhered to the biological 
membrane and hence capable of prolonging the contact time of the drug with a body 
tissue. The use of bioadhesive polymers can significantly improve the performance 
of many drugs. This improvement ranges from better treatment of local pathologies 
to improved bioavailability and controlled release to enhance patient compliance.  
Characteristics of Ideal Bioadhesive Polymers  
 It should show bioadhesive properties in both dry and liquid state.  
 It should possess an optimum molecular weight to the bioadhesion.  
 It should be able to accommodate both oil and water soluble drugs for the  
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 Purpose of controlled drug delivery.  
 It should demonstrate local enzyme inhibition and penetration enhancement 
properties.  
 It should show specificity for attachment to an area or cellular site.  
 It should show specificity and stimulate endocytosis.  
 It should be inert and compatible with the environment.  
 It should be easy and inexpensive to fabricate.  
 It should have good mechanical strength.  
 It should possess a wide margin of safety both locally and systemically. 
(Pankil A. Gandhi et al., 2011) 
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CHAPTER III 
LITERATURE REVIEW 
Sellappan Velmurugan et al., 2013, formulated and evaluated Glipizide 
mucoadhesive buccal tablets. The tablets were prepared by direct compression 
technique using different concentrations of mucoadhesive polymers such as Carbopol 
940, Sodium Alginate and HPMC K15M in combination. The formulated tablets 
were evaluated for bioadhesive strength, surface pH, in-vitro drug release. The 
formulation containing 1:8 ratio of drug and polymer combination showed 
satisfactory bioadhesion and optimum drug release (72.35±0.04% after 12 hours). 
Satyabrata Bhanja et al., 2013, formulated and evaluated the mucoadhesive buccal 
tablets containing anti diabetic drug, Glimepiride to circumvent the first pass effect 
and to improve the bioavailability with reduction in dosing frequency and dose 
related side effects. The tablets were prepared by direct compression method. Six 
formulations were developed with varying concentrations of  polymers like Carbopol 
934P, HPMCK4M, and chitosan. The tablets were tested for weight variation, 
hardness, surface pH, drug content, swelling index, bioadhesive strength, ex-vivo 
residence time, in-vitro dissolution study, in-vitro drug release kinetic studies, ex-
vivo permeation study and stability studies. FTIR studies showed no evidence on 
interaction between drug, excipients. The best in-vitro drug release profile was 
achieved with the formulation F3 which contains the drug, carbopol 934P, HPMC 
K4M and chitosan in the ratio of 1:3.75:8.75:1.25. Finally it was concluded that the 
best formulation F3 was suitable for all the evaluation parameters and can be 
permeated through human buccal mucosa. 
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Patil K C et al., 2013, formulated and evaluated buccoadhesive tablets of  Captopril  
using  mucoadhesive polymers. The tablets were prepared by direct compression 
technique using Carbopol 934P, HPMC K15M and Hydroxy ethyl cellulose as 
mucoadhesive polymers. Six formulations were developed with varying 
concentration of polymers. Formulation (F1) containing Carbopol 934P and HPMC 
K4M in the ratio of (1:2) showed good mucoadhesive strength (18.55) and maximum 
drug release of 97.66% in 10 hours. Swelling increased with increasing in 
concentration of Carbopol 934P in tablets. FTIR studies showed no evidence on 
interaction between drug and polymers. The result indicated that the mucoadhesive 
buccal tablets of Captopril may be good choice to bypass extensive hepatic first pass 
metabolism with an increased bioavailability of Captopril. 
Ankarao  A et al., 2013, formulated and evaluated buccoadhesive bilayer tablets of 
carvedilol. The tablets were prepared using HPMC K4M, SCMC and Carbopol 934 
as bioadhesive polymers to impart mucoadhesion and ethyl cellulose to act as an 
impermeable backing layer. The mechanism of drug release was found to be non-
Fickian diffusion (value of n between 0.5 and 1.0). The study was concluded that 
mucoadhesive tablets of Carvedilol can be a good way to bypass the extensive 
hepatic first-pass metabolism and to improve the bioavailability of Carvedilol. 
Muthadi Radhika et al., 2013, formulated and evaluated buccoadhesive bilayer 
tablet of  Enalapril Maleate. Tablets of Enalapril Maleate were prepared by direct 
compression method using bioadhesive polymers like Carbopol 934P, HPMC K15M, 
HPMC K100M either alone or in combination with backing layer of ethyl cellulose. 
The maximum bioadhesive strength was observed in tablets formulated with 
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Carbopol 934P alone. Carbopol 934P and HPMC K100 in the ratio of 1:1.5 could be 
used to design effective and stable buccoadhesive tablets of Enalapril Maleate. 
Muthukumaran M et al., 2013, developed and optimized Hydralazine HCL 
sustained release mucoadhesive buccal tablets using 2
3 
factorial design. The 
bioadhesive polymers such as Xanthan gum, Carbopol and HPMC were used in 
combination with ethyl cellulose and magnesium stearate as an impermeable backing 
layer. The 2
3 
full factorial design was employed by selecting the independent three 
polymer variables at two levels (low and high level). The study was successfully 
undertook the development of an optimized mucoadhesive and sustained release 
characteristics. Finally he concluded that mucoadhesive bilayer tablets of 
Hydralazine HCL could be promising one as they increases bioavailability, 
minimizes the dose, reduces the side effects and improved patient compliances.  
Raviteja Achanta et al., 2013, developed and evaluated buccoadhesive bilayered 
tablets of Thiocolchicoside. The tablets were prepared using bioadhesive polymers 
like Carbopol 934P, HPMC by direct compression method. Ethyl cellulose used as 
an impermeable backing layer which gives unidirectional buccal drug delivery. The 
results of study revealed that the formulation containing a combination of polymers 
like Carbopol 934P and HPMC K4M showed suitable in-vitro drug release. These 
buccoadhesive bilayered tablets were developed to a satisfactory level in terms of 
drug release, bioadhesive time, physicochemical properties and surface pH. 
Gururaj S Kulkarni et al., 2013, developed and evaluated Terbutaline sulphate 
mucoadhesive buccal tablets. In this study, the attempt was made to prepare 
mucoadhesive buccal tablets of Terbutaline sulphate with natural polymer sodium 
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alginate with one side absorption by backing layer with ethyl cellulose. IR 
spectroscopy did the compatible study between polymers and Terbutaline sulphate 
and no interaction was found between drug and polymers. All parameters of 
Terbutaline sulphate buccal tablets were passed the standard of mucoadhesive buccal 
tablets. It was found that mucoadhesive natural polymers exhibited better 
adhesiveness and mucoadhesiveness. The in-vitro study of terbutaline sulphate 
exhibited greater drug release profile with release in the range of 79.25 to 99.85%. 
Raviteja Achanta et al., 2012, developed and evaluated buccoadhesive tablets of 
Losartan Potassium. The buccal route is suitable for drugs, which are susceptible to 
acid hydrolysis in the stomach or which are extensively metabolized in the liver(first 
pass metabolism). Losartan Potassium buccoadhesive tablets were prepared by direct 
compression method using different polymers such as Carbopol 934P, HPMC K4M, 
HPMC K15LV. In order to increase bioavailability to avoid the hepatic metabolism, 
the buccal tablets of Losartan Potassium were prepared. 
Bhaskar Umaraj et al., 2012, fabricated and evaluated the mucoadhesive buccal 
tablets of furosemide by wet granulation method using Chitosan, Guar Gum and 
Hydroxy ethyl cellulose along with Carbopol 934P as mucoadhesive polymers in 
different ratios. As the amount of polymer in the tablets increases, the drug release 
rate decreases, whereas swelling index and mucoadhesive strength increases. Ex-vivo 
residence test for mucoadhesion indicated good mucoadhesive property of the 
prepared tablets. The formulations containing polymers such as Carbopol 
934P:Chitosan and Carbopol 934P:Guar Gum were optimised because of their good 
mucoadhesive strength. 
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Appa Rao Potu et al., 2012, formulated and evaluated buccoadhesive Quetiapine 
Fumarate tablets. The tablets were prepared using HPMC K4M, HPMC K15M and 
combination of Carbopol and Hydroxy Ethyl Cellulose as mucoadhesive polymers 
by direct compression method. Sodium deoxycholate  was added to formulation to 
improve the permeation of drug. The formulation were tested for bioadhesion 
strength, ex-vivo residence time, swelling time and in-vitro dissolution studies. 
Optimized formulation showed 92% in-vitro release in 8 hours and 67% permeation 
of drug through porcine buccal mucosa. These findings suggested that buccoadhesive 
tablets of Quetiapine Fumarate showed significant improvement in oral 
bioavailability of the drug. FTIR spectra of optimized formulation showed no drug-
polymer interaction. 
Anand Padole et al., 2012, prepared and evaluated buccal mucoadhesive tablets of 
lisinopril. The tablets were prepared by direct compression method using different 
hydrophilic polymers such as hydroxyl propyl methyl cellulose and carbopol. The 
friability of all the formulations were  below 1% which is an indication of good 
mechanical resistance of tablets. No colour change or no changes in texture were 
observed when tablets were tested in simulated saliva solution(pH 6.8). The tablet 
with polymers such as Carbopol 934P:HPMC K4 in the ratio of 2:1 showed 
maximum swelling index, bioadhesive strength. Novel mucoadhesive buccal tablets 
of Lisinopril were developed to overcome the first pass metabolism and subsequent 
low bioavailability of the Lisinopril. The in-vitro studies have shown that this is a 
potential drug delivery system for Lisinopril with a considerably good stability and 
release profile. 
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Vinod Kombath Ravindran et al., 2012, done a project on comparative study of 
mucoadhesive polymers such as Carbopol 974P and Sodium carboxy methyl 
cellulose for single unit dosage of Imatinib Mesylate. Gastro retentive mucoadhesive 
mucoadhesive tablet was prepared by direct compression method using Carbopol 
974P and SCMC as mucoadhesive polymers. Drug release profile using the SCMC 
was preferred to the Carbopol 974P. Hence SCMC can be optimized although 
Carbopol 974P showed better adhesive nature. 
Muthukumaran M et al., 2012, fabricated and evaluated sustained release 
mucoadhesive bilayer tablets containing Nifedipine. The tablets were prepared by 
direct compression method using the natural bioadhesive polymers such as Pectin to 
compare the synthetic polymer such as Carbopol 971P, HPMC K4M and Polyvinyl 
Pyrrolidine(PVP K30) along with Ethyl Cellulose and Magnesium Stearate as an 
impermeable backing layer to improve the oral bioavailability. The preformulation 
was performed by FTIR and DSC. The formulated Nifedipine buccal tablets showed 
a significant increase in oral bioavailability. Higher bioavailability would be due to 
avoidance of hepatic first pass metabolism by intestinal lymphatic transport, which 
circumvents the liver. It was concluded that the dose of Nifedipine buccal tablets 
needs to be decreased in accordance with increased bioavailability, to minimize its 
dose related adverse effects. 
Ananda Reddy K et al., 2012, formulated and evaluated buccal adhesive tablets of 
Piroxicam. The tablets were prepared by HPMC K4M and Carbopol 934 as 
mucoadhesive polymers. The formulations were developed with varying 
concentrations of polymers such as HPMC K4M and Carbopol 934. The formulation 
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containing drug:HPMC K4M(in the ratio of 1:3) showed maximum release of 
drug(97.67% ± 0.41%). FTIR results showed no evidence of interaction between the 
drug and polymers. 
G V Wadageri et al., 2012, developed and evaluated mucoadhesive bilayer buccal 
tablets of Carvedilol. In this study, an attempt was made to design and evaluate 
buccoadhesive bilayer tablets of Carvedilol, in order to overcome bioavailability 
problems, to reduce dose dependent side effects and frequency of administration. 
Tablets were prepared by direct compression method using combination of 
polymers(such as HPMC K15M and K4M along with Carbopol 934P and EC as 
backing layer). The formulation containing HPMC 15CPS(48%W/W), Carbopol 
934P(2%W/W of matrix layer) and mannitol was found to be promising. This 
formulation exhibited an in-vitro drug release of 84.73% in 8 hours along with 
satisfactory bioadhesion strength(5.17g). 
Raghavendra Rao N. G et al., 2012, formulated and evaluated mucoadhesive 
buccal bilayered lablets of Salbutamol. The tablets were fabricated with objective of 
avoiding first pass metabolism and prolonging duration of action. The tablets were 
prepared by direct compression method using the bioadhesive polymers such as 
Xanthan Gum, Sodium Alginate and Carbopol 934P with Ethyl Cellulose as an 
impermeable backing layer. The FTIR results revealed that there was no interaction 
between drug and other excipients. The study concluded that mucoadhesive buccal 
tablets of Salbutamol can be a good way to bypass the extensive hepatic first pass 
metabolism and improved the bioavailability. 
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Suresh kumar P et al., 2011, formulated and evaluated Nebivolol mucoadhesive 
buccal tablets. The oral controlled release Nebivolol mucoadhesive tablets by using 
HPMC K4M, HPMC K15M and Carbomer 940 as  mucoadhesive polymers were 
prepared by direct compression method and evaluated for mucoadhesive strength and 
in-vitro dissolution parameters. This study suggests the polymer HPMC K15M can 
produce a controlled pattern of drug release in the prepared Nebivolol tablets. The 
high mucoadhesive strength of this formulation was likely to increase its residence 
time in the GIT, which eventually improves the extent of bioavailability. 
Basawaraj S. Patil et al.,2011, developed and evaluated mucoadhesive buccal 
tablets of Tizanidine hydrochloride using natural polymer Guar gum. The tablets 
were prepared by using Guar gum and in combination of Guar gum with Sodium 
alginate as mucoadhesive polymers. The in-vitro performances were evaluated by 
drug content uniformity, surface pH, swelling index, mucoadhesive strength and 
dissolution studies. The swelling index and mucoadhesivity of the tablets were 
increased with increasing amount of Guar gum and sodium alginate. So it can be 
concluded that mucoadhesive buccal tablets of Tizanidine hydrochloride can be 
prepared by using natural polymers avoids first pass metabolism. 
Gaurav kumar et al., 2011, fabricated and evaluated flavoured mucoadhesive 
buccal tablets of Caffeine as CNS stimulantt. Mucoadhesive buccal dosage form of 
Caffeine anhydrous was designed using a combination of bioadhesive polymers such 
as Carbopol 934P, HPMC, and SCMC in different ratios. Carbopol 934P showed 
maximum bioadhesion property. The formulations were tested for their swelling 
behavior. In which the formulation containing SCMC and Carbopol 934P was found 
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to be swell  to a greater extent than those containing SCMC and HPMC. In-vitro 
release studies showed that the formulation consisting of 3:1 ratio of SCMC and 
Carbopol 934P released Caffeine over 8 hours. Caffeine release and bioadhesion of 
buccal tablets can be controlled by changing the polymer type and concentration. 
Ranade A N et al., 2011, developed and evaluated buccal tablets of Quinapril 
hydrochloride. Quinapril hydrochloride was reported to have low oral bioavailability 
due to an extensive first pass effect. Buccoadhesive tablets of Quinapril 
hydrochloride were prepared using mucoadhesive polymers such as Carbopol 974P, 
HPMC K4M. Citric acid was chosen as permeation enhancer. The tablets were 
prepared by direct compression technique. DSC studies showed no interaction 
between drug and excipients. The buccoadhesive tablet of Quinapril hydrochloride 
was prepared using CP and HPMC provided regulated release upto 3 hours. The 
presence of penetration enhancer indicated increased penetration of drug across the 
buccal mucosa which can result in improved bioavailability. 
Pankil A Gandhi et al., 2011, done a study on mucoadhesive buccal drug delivery 
system. The buccal region of oral cavity was found to be an attractive target for 
administration of the drug of choice, particularly in overcoming deficiency 
associated with the later mode of administration. Problems such as high first pass 
metabolism drug degradation in the gastrointestinal environment can be 
circumvented by administering the drug via the buccal route. Moreover, rapid onset 
of action can be achieved relative to the oral route and the formulation can be 
removed if the therapy is required to be discontinued. It is also possible to administer 
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drugs to patients who unconscious and less co-operative. The buccal mucosa offers 
several advantages for controlled drug delivery for extended period of time. 
Anay R Patel et al., 2011, done a study on mucoadhesive buccal drug delivery 
system. Within the oral mucosal cavity, the buccal region offers an adorable route of 
administration for systemic drug delivery. Among the various transmucosal sites 
available, mucosa of the buccal cavity was found to be the most convenient and 
easily approachable as retentive dosage forms. sites for the delivery of therapeutic 
agents for both local and systemic delivery as retentive dosage forms. The 
mucoadhesive interaction was explained in relation to the structural characteristics of 
mucosal tissues and the theories and properties of the polymers. 
Vijaya Muthumanikandar R et al., 2011, developed and evaluated buccoadhesive 
tablets of Losartan Potassium. Buccoadhesive tablets were prepared by wet 
granulation method using the Carbopol 934P, Hydroxy propyl cellulose, Sodium 
Alginate and SCMC as bioadhesive polymers. The tablets were evaluated for pre and 
post compression parameters like bioadhesive strength, in-vitro retention time and in-
vitro drug release studies. The formulation containing Carbopol and HPC  shows 
higher bioadhesive strength, sustained release of drug and sufficient in-vitro retention 
time. 
Agaiah Goud et al., 2011, formulated and evaluated bioadhesive buccal tablets of 
Simvastatin. Simvastatin has short biological half life(3 hours), high first pass 
metabolism and poor oral bioavailability(5%), hence an ideal candidate for buccal 
delivery system. The tablets were prepared by direct compression technique using 
Carbopol 934, SCMC and HPMC as mucoadhesive polymers. The formulations were 
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evaluated for mass variation, hardness, friability, drug content, swelling studies, 
erosion studies, in-vivo residence time, in-vitro release studies in pH 7.0 phosphate 
buffer with 0.5% SDS and ex-vivo permeation studies through porcine buccal 
mucosa. FTIR studies showed no evidence on interaction between drug, polymers 
and other excipients. The prepared bioadhesive buccal tablets of Simvastatin could 
help bypass extensive hepatic first pass metabolism and improved bioavailability. 
The buccal tablets showed that SCMC containing formulations showed better 
bioadhesion than the HPMC K4M. The drug release rate of formulations prepared 
with HPMC K4M(max.60.67%) was retarded due to the high viscosity of the 
polymer and formation of complex matrix network when compared to the low 
viscosity polymers SCMC(max.78.77%). 
Goswami Dhruba Sankar et al., 2011, formulated and evaluated mucoadhesive 
tablets of Famotidine. The tablets were prepared by conventional wet granulation 
method employing HPMC K4M, SCMC, Sodium Alginate, Acacia and Tragacanth 
as mucoadhesive materials to reduce the dosing frequency. The formulations were 
subjected to different evaluation studies like friability, content uniformity, surface 
pH. The result showed that formulation containing Famotidine with HPMC K4M and 
Tragacanth has given better drug release property and better mucoadhesive property. 
Lokhande S et al., 2011, formulated and evaluated buccoadhesive tablets of 
Atenolol. The present study was aimed to formulate the buccoadhesive tablet of 
Atenolol by adopting Box-Behnken factorial design and  using Chitosan, Carbopol 
937P and SCMC. The formulations were evaluated for drug content, hardness, 
thickness, friability, weight variation, in-vitro dissolution study and ex-vivo 
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bioadhesive strength and time. The ex-vivo bioadhesion studies formulations on 
sheep buccal mucosa showed better bioadhesion with high bioadhesion time. In-vitro 
drug release studies indicated that the drug release was higher and controlled when 
the polymer content(Carbopol 937P and Chitosan) was 100mg per tablet. The release 
of Atenolol was controlled by the diffusion from the matrix formed by the polymers. 
Oral controlled release bioadhesive tablets of Atenolol were formulated as an 
approach to avoid fluctuations in plasma drug concentration and thereby to improve 
its bioavailability. 
Amit Alexander et al., 2011, done a study on polymers and permeation enhancers as 
a specialized components of mucoadhesives. Mucoadhesive polymers recently 
gained interest among pharmaceutical scientists as a means of improving drug 
delivery by promoting dosage form residence time and contact time with the mucous 
membranes. Pharmaceutical aspects of mucoadhesion have been the subject of great 
interest during recent years because mucoadhesion could be a solution for 
bioavailability problems.  
Santanu Roychowdhury et al., 2011, done a study on buccal mucoadhesive drug 
delivery systems. Buccal mucosa is the preferred site for both systemic and local 
drug action. The mucosa has a rich blood supply it relatively permeable. In this 
article the advantages and limitations related to the buccal drug delivery has also 
been discussed. In buccal drug delivery systems mucoadhesion is the key element so 
various mucoadhesive polymers have been utilized in different dosage form. Various 
mucoadhesive dosage forms such as Chewing gum, Patches, Tablets, Hydrogel, 
Thiolated  tablets are discussed in this review article. Finally he concluded that 
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buccal region provides  a convenient route for both local and systemic drug actions. 
Buccal adhesive systems offer innumerable advantages in term of accessibility, 
administration and withdrawal, retentivity, low enzyme activity, economy and high 
patients compliance. The future direction of buccal adhesive drug delivery lies in 
vaccine formulations and delivery of small proteins/peptides. 
Yadav Deepak R et al., 2011, developed and evaluated  buccoadhesive  
Metoclopramide Hydrochloride tablet formulations. Tablets were fabricated by direct 
compression method with objective of avoiding extensive first pass metabolism and 
to prolong its duration of action with reduction in dosing frequency. The  
mucoadhesive polymers used in the formulations were Carbopol 934P, Chitosan, 
HPMC K4M and HPMC K15M. Formulation (F4) containing Carbopol 934P and 
HPMC K4M in the ratio of 1:1 showed good mucoadhesive force and maximum 
drug release of 96.10% in 10 hours. He concluded that mucoadhesive buccal tablets 
of Metoclopramide may be a good way to bypass the extensive  hepatic first-pass 
metabolism and to improve the bioavailability of Metoclopramide. 
Jitendra kumar P et al., 2011, formulated and evaluated buccoadhesive bilayered 
tablets of Carvedilol. The tablets were prepared using HPMC K4M, CMC Sodium, 
Carbopol 934 as bioadhesive polymers to impart mucoadhesion and ethyl cellulose to 
act as an impermeable backing layer. Buccal tablets were evaluated by different 
parameters such as weight uniformity, content uniformity, thickness, hardness, 
surface pH, swelling index, mucoadhesive strength, drug release and in-vitro drug 
permeation. The mechanism of drug release was found to be non-Fickian diffusion 
(value of n between 0.5 and 1.0) for both the buccal tablets (F2 and F5). Finally he 
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concluded that mucoadhesive buccal tablets of Carvedilol may be a good way to 
bypass the extensive hepatic first-pass metabolism and to improve the bioavailability 
of Carvedilol through buccal mucosa. 
Gaurav Kumar et al., 2011, fabricated and evaluated flavoured mucoadhesive 
buccal tablet of caffeine as CNS stimulant. In this study, a bioadhesive dosage form 
of caffeine anhydrous was designed using a combination of bioadhesive 
polymers(sodium carboxymethyl  cellulose, Carbopol 934P and Hydroxy propyl 
methyl cellulose) in different ratios. Carbopol 934P showed maximum bioadhesion. 
The formulations were tested for their testing behavior using the agar gel plate 
method in which formulations containing sodium carboxymethyl cellulose and 
Carbopol was found to swell to a greater extent than those containing sodium 
carboxymethyl cellulose ang Hydroxy propylmethyl cellulose. In-vitro release 
studies showed that the formulation consisting of 3:1 ratio of sodium carboxymethyl 
cellulose and Carbopol 934P released Caffeine over 8 hours. Finally it was 
concluded that this noval formulations can reduce the need of frequent administration 
and enhanced patient compliance with better absorption through buccal route. 
Shivanand K et al., 2010, fabricated and evaluated Mucoadhesive bilayered buccal 
tablets of Tizanidine Hydrochloride, using mucoadhesive polymers Carbopol 934P, 
HPMC K4M, HPMC K15M and Sodium carboxymethyl cellulose along with ethyl 
cellulose as an impermeable backing layer. The preformulation studies of TZD HCL 
like compatibility studies with polymers, using FTIR and DSC were carried out. The 
tablets were evaluated for weight variation, hardness, thickness, surface pH, 
mucoadhesive strength, mucoadhesive time, swelling index, in-vitro drug release 
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studies and ex-vivo permeation. He concluded that CArbopol 934P was more 
hydrophilic than HPMC, so it could swell rapidly. Therefore decrease of Carbopol 
content delayes the drug release.drug release rate was increased with increasing 
amount of hydrophilic polymer. 
Ravi Krishna V et al., 2010, formulated and evaluated buccoadhesive tablets of 
Furosemide. The tablets of Furosemide were prepared by direct compression method 
using bioadhesive polymers like Carbopol 941NF, 971P, Methocel K4M, Methocel 
K15M and combination of SCMC, Carbopol 971P in different ratios with backing 
layer of Cyanoacrylate adhesive tape. Buccal tablets were evaluated by different 
methods for parameters such thickness, hardness, weight uniformity, swelling index, 
surface pH, ex-vivo bioadhesion strength, ex-vivo residence time, in-vitro drug 
release, in-vitro drug release, ex-vivo drug permeation, stability studies, in-vivo 
mucoadhesive performance studies. Bioadhesion strength was increased with 
increase in the concentration of Carbopol. The buccal adhesive tablets of Furosemide 
were found to be good choice to bypass the first pass metabolism. 
Guda Aditya et al., 2010, designed and evaluated controlled release mucoadhesive 
buccal tablets of Lisinopril. Tablets were prepared by direct compression method 
using various polymers such as Carbopol 934, HPMC, Hydroxy Ethyl Cellulose as 
mucoadhesive polymers. The tablets were evaluated for hardness, wait variation, 
thickness, percentage of drug content, surface pH, in-vitro studies like swelling, 
mucoadhesive strength. The formulation containing Carbopol 934 and HPMC K4M 
in the ratio of 2:4 showed good mucoadhesive strength(36.4) and maximum drug 
release of 97.1% in 10 hours. So, the mucoadhesive buccal tablet of Lisinopril may 
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be a good choice to bypass the extensive hepatic first pass metabolism with an 
improvement in the bioavailability of Lisinopril through buccal mucosa. 
Punitha S et al., 2010, done a study on polymers in mucoadhesive buccal drug 
delivery system. Among the various transmucosal sites available, mucosa of the 
buccal cavity was found to be the most convenient and easily accessible site for the 
delivery of therapeutic agents for local and systemic delivery as retentive dosage 
forms. The success and degree of mucoadhesion bonding was influenced by various 
polymer based properties. Buccal adhesive system offered innumerableadvantages in 
terms of accessibility, administration and withdrawal, retentivity, low enzymatic 
activity, economy and high patient compliance. 
Bhanja Satyabrata et al., 2010, designed and evaluated mucoadhesive buccal 
tablets of perindopril by sintering technique to avoid the first pass metabolism and to 
improve its bioavailability with reduction in dose and also dose related side effects. 
The tablets were prepared by direct compression method containing polymer Poly 
ethylene oxide and Carnauba Wax. The prepared tablets were sintered at various 
temperature like 60
0
C and 70
0
C for 1.5 hours and 3 hours. The best in-vitro drug 
release profile was achieved with formulation(sintered at 60
0
C for 1.5 hours) 
containing drug, Polyethylene Oxide and Carnauba Wax in the ratio of 1:15:10. So 
mucoadhesive buccal tablets of perindopril prepared by sintering technique may be 
good approach to bypass the extensive first pass metabolism, to improve the 
bioavailability to prolong the duration of action. 
Satyabrata Bhanja et al., 2010, formulated and evaluated mucoadhesive buccal 
tablets of Timolol maleate to circumvent the first pass effect and to improve its 
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bioavailability with reduction in dosing frequency and dose related side effects. The 
tablets were prepared by direct compression with varying concentration of polymers 
like Carbopol 934, Poly ethylene oxide and HPMC. FTIR studies showed no 
evidence on interactions between drug, polymers and excipients. The best in-vitro 
drug release profile was achieved with the formulation which contains the drug, 
Carbopol 934P and HPMC K4M in the ratio of 1:2.5:10. It can be seen that by 
increasing the concentration of Carbopol 934P in the formulation, the drug release 
rate from the tablets was found to be decreased. But when the concentration of 
HPMC K4M increased, the drug release rate was found to be increased. 
Hiremath J G et al., 2009, prepared and characterized Simvastatin loaded 
mucoadhesive bilayered tablets. The purpose of this research work was to prepare the 
buccoadhesive bilayered tablet of Simvastatin for the treatment of 
hypercholesterolemia, by using the buccoadhesive polymers such as Carbopol(CP), 
HPMC and PVP in different concentration. Ethyl Cellulose was used in backing 
layer because of its water impermeable nature. Tablets were prepared by direct 
compression method. Tablets were subjected for physicochemical characterization 
tests such as FTIR, DSC, hardness, weight variation, friability, mucoadhesive 
strength, in-vitro drug release study, in-vitro permeation and stability in human 
saliva. The FTIR and DSC analysis of drug, polymers, physical mixtures and 
formulation indicated that the compatibility of drug with the excipients. The study 
was concluded that mucoadhesive buccal devices of Simvastatin can be a good way 
to bypass the extensive hepatic first pass metabolism and to improve the 
bioavailability of Simvastatin. 
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Deelip Derle et al., 2009, formulated and evaluated bioadhesive Bi-layered tablet of 
Propranolol Hydrochloride using the bioadhesive polymers such as Sodium Alginate 
and Carbopol 971P along with Ethyl Cellulose as a impermeable backing layer. The 
tablets were Sodium Alginate and Carbopol 971P in the ratio of 5:1 showed the 
maximum percentage of in-vitro drug release without disintegration in 12 hours. The 
mechanism of drug release was found to be zero order kinetics. The mucoadhesive 
buccal tablets of Propranolol hydrochloride can help to bypass extensive hepatic first 
pass metabolism and hence improve bioavailability. 
Margret Chandira R et al., 2009, designed and developed controlled release 
mucoadhesive oral tablet of Clarithromycin. He formulated the tablets using four 
mucoadhesive polymers namely Carbopol 974P, HPMC K4M and HPMC K15M.   
Formulations F9 and F12 were formulated by using polymers, HPMC K4M, HPMC 
K15M and Carbopol provided controlled release of Clarithromycin over the period of 
12 hours. Tablets of batch F9 and F12 were selected as an optimum batch and 
evaluated for further parameters like accelerated stability study and characterization 
using IR spectroscopy. The stability study revealed that there was no significant 
change in dissolution profile and mucoadhesive strength for a period of one month. 
Manivannan R et al., 2008, formulated and evaluated mucoadhesive buccal tablets 
of Diltiazem Hydrochloride. The tablets were prepared using Carbopol 934, SCMC, 
HPMC, Sodium Alginate and Guar Gum as mucoadhesive polymers. The Carbopol 
934 was used as a primary polymer because of its excellent mucoadhesive property 
and secondary polymers like HPMC, SCMC, Sodium Alginate and Guar Gum were 
used. The formulations were tested for in-vitro drug release and in-vitro swelling 
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studies. Formulation with drug:Carbopol(in the ratio of 1:4) showed maximum 
release of 76.98% in 8 hours and swelling index of 3.7 after 8 hours. Formulations 
followed zero order drug release. FTIR showed no evidence on interaction between 
drug and polymers. 
Ganesh P et al., 2008, developed and evaluated mucoadhesive buccal tablets of 
Domperidone. The tablets were prepared fabricated with objective of avoiding first 
pass metabolism and to improve its bioavailability with reduction in dosing 
frequency. The mucoadhesive polymers used in the formulations were Carbopol 
934P, Methocel K4M, Methocel E15LV and Chitosan. Tablets were prepared by 
direct compression method using polymers in different ratios. The formulations were 
characterized for swelling index, in-vitro bioadhesion strength and in-vitro release 
studies. The best mucoadhesive performance and in-vitro drug release profile were 
exhibited by the tablet containing Chitosan and Methocel K4M in ratio of 1:1. It was 
observed that the optimized formulation followed Hixson Crowel  release kinetics. 
Johnson. P et al., 2005, done a project on the use of mucoadhesive polymers in 
buccal drug delivery. Buccal delivery involves the administration of the desired drug 
through the buccal mucosal membrane lining of the oral cavity. Unlike oral drug 
delivery, which presents a hostile environment for drugs, especially proteins and 
polypeptides, due to acid hydrolysis and the hepatic first pass metabolism, the 
mucosal lining of buccal tissues provides much milder environment for drug 
absorption. Starting with a review of the oral mucosa, mechanism of drug 
permeation, and characteristics of the desired polymers, this article then proceeds to 
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cover the theories behind the adhesion of bioadhesive polymers to the mucosal 
epithelium.  
Yasuko Obata et al., 2002, done a project on buccal absorption of Ergotamine 
tartrate using the bioadhesive tablet system in guinea pigs. The tablets were prepared 
by direct compression method using Carboxy vinyl polymers and Hydroxy propyl 
cellulose(1%W/W) as a mucoadhesive polymers. Buccal tablet showed better 
absorption of Ergotamine Tartrate compared with Polyvinyl alcohol gel in Guinea 
pig. 
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CHAPTER IV 
AIM OF THE WORK 
Nowadays, tablet dosage forms are supplanted by new drug delivery system 
because of problems like hepatic metabolism, GI toxicity which leads to non- 
compliance and ineffective therapy. This problem can be overcome by formulating 
the drug in to buccal adhesive tablets for mucosal absorption with reduced GI 
toxicity, hepatic first pass metabolism and improved bioavailability. Moreover, rapid 
onset of action can be achieved relative to the oral route. The main mechanism 
behind buccal mucoadhesion is the formation of an intimate contact between the 
dosage form and the absorptive buccal mucosa. Buccal adhesive formulations are 
mainly supported by mucoadhesive polymers as the adhesive component. 
Olmesartan medoxomil is a angiotensin receptor II antagonist used alone or 
with other antihypertensive agent. Olmesartan medoxomil is the most recent member 
of angiotensin receptor blocker which is chemically, (5-methyl-2-oxo-2H-1, 3-
dioxol-4-yl) methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1 - ({4- [2-(2H-1, 2, 3, 4-
tetrazol-5-phenyl] phenyl} methyl)-1H-imidazole-5-carboxylate. 
  Olmesartan medoxomil is practically insoluble in water, freely soluble in 
organic solvents.  It  is a novel antihypertensive agent administered orally with 
absolute bioavailability of about 26% due to extensive hepatic first pass metabolism.  
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 The main aim of this study is to formulate and evaluate buccal adhesive 
tablets of olmesartan medoxomil using varios mucoadhesive polymers such as 
carbopol 934P, HPMC K15M, sodium carboxymethyl cellulose, chitosan and 
xanthan gum for reducing its hepatic first pass metabolism, dose reduction and 
controlled release of drug with improved bioavailability and also to target the drug at 
its specific site of absorption (buccal mucosa).  
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CHAPTER V 
PLAN OF WORK 
1. PREPARATION OF STANDARD CALIBRATION CURVE OF 
OLMESARTAN MEDOXOMIL 
(a) Preparation of phosphate buffer pH 6.8 
(b) Determination of λmax of olmesartan medoxomil 
(c) Preparation of calibration curve of olmesartan medoxomil 
2. PREFORMULATION (COMPATABILITY) STUDIES  
(a) Fourier transform infrared spectroscopic studies (FTIR) 
3. FORMULATION OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE 
TABLETS 
             Preparation of buccal adhesive tablets of olmesartan medoxomil using 
different concentrations of hydrophilic swellable gel forming polymers 
(carbopol 934P, HPMC K15M, sodium carboxy methyl cellulose, chitosan, 
xanthan gum) by using direct compression technique. 
4. EVALUATION OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE 
TABLET 
I. Pre compressional evaluation of powder blend 
(a) Bulk density (gm/ml) 
(b) Tapped density (gm/ml)  
(c) Compressibility (or) Carr’s  Index  
(d) Hausner's ratio 
(e) Angle of repose () 
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(f) Drug content of powder blend            
II. Post compressional evaluation of buccal adhesive tablet 
(a) General appearance 
(b)Tablet dimension  
(c) Hardness test 
(d) Friability test   
(e) Weight variation test  
(f) Estimation of drug content for tablets 
(g) Determination surface pH  
(h) Ex-vivo mucoadhesive strength  
  (i) Swelling index studies  
(j) In vitro release studies  
  (k) In vitro drug release kinetics studies   
5.  SELECTION AND EVALUATION OF BEST FORMULATION 
  (a)  Infrared spectroscopic studies (IR) 
            (b) Differential scanning calorimetric studies (DSC) 
(c)  Stability studies 
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CHAPTER VI 
FORMULATION AND EVALUATION OF MUCOADHESIVE 
BUCCAL TABLETS OF OLMESARTAN MEDOXOMIL 
 
MATERIALS: 
MATERIAL NAME SUPPLIERS 
Olmesartan Medoxomil 
Gift sample from Medopharm (P) Ltd, 
Chennai. 
Carbopol 934 SD Fine Chemicals, Mumbai. 
HPMC K15M 
Steril-gene Life Sciences (P) Ltd, 
Pondicherry. 
Xanthan Gum 
Steril-gene Life Sciences (P) Ltd, 
Pondicherry. 
Sodium carboxy methyl cellulose 
Steril-gene Life Sciences (P) Ltd, 
Pondicherry. 
Chitosan 
HiMedia Laboratories (P) Ltd, 
Mumbai. 
Lactose 
Steril-gene Life Sciences (P) Ltd, 
Pondicherry. 
Mannitol 
Steril-gene Life Sciences (P) Ltd, 
Pondicherry. 
Magnesium stearate 
Universal Scientific Appliances, 
Madurai, India. 
Talc 
Universal Scientific Appliances, 
Madurai, India. 
Methanol 
Universal Scientific Appliances, 
Madurai, India 
Sodium Hydroxide 
High Purity Laboratory Chemicals (P) 
Ltd. 
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EQUIPMENTS 
NAME MANUFACTURER 
Electronic Weighing Balance    A & D Company HR 200, Japan 
Single Punch Tablet Compression 
Machine 
Cadmach Machinery Co. Pvt. Ltd, 
Ahmadabad. 
UV Visible Spectrophotometer 
UV-1700 Pharmaspec, Shimadzu, 
Japan. 
Digital Tablet Dissolution Test 
Apparatus 
Disso 2000, Lab India, Mumbai. 
Friability Test Apparatus 
Indian Equipment Corporation, 
Mumbai. 
Vernier Caliper                    Linker, Mumbai. 
Tablets hardness tester( Monsanto) Praveen Enterprises, Bangalore. 
Fourier Transform Infrared 
Spectroscopy 
Shimadzu , Japan 
 
Modified Physical Balance 
 
ASIA Scientific Company, India. 
Differential Scanning Calorimeter                 DSC Q 200, Mumbai 
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CHAPTER VII 
DRUG PROFILE 
DRUG NAME   : OLMESARTAN 
SYNONYM    : Olmesartan medoxomil 
STRUCTURE: 
 
FORMULA    : C24H26N6O3   
MOLECULAR WEIGHT  : 446.5 
SYSTEMATIC IUPAC NAME :
 
4-(2-hydroxypropan-2-yl)-2-propyl-1-
({4-[2-(1H-1,2,3,4-tetrazol-5-yl-)phenyl] 
phenyl} methyl)-1H-imidazole-5-carboxylic 
acid                       
 
APPEARANCE   : White to pale yellowish powder 
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SOLUBILITY : Practically insoluble in water, sparingly 
soluble in          methanol        
MELTING POINT   : 175-180º c  
PKa     : 4.3                                                               
PARTITION COEFFICIENT : Log P 2.14 
HALF LIFE    : Approximately 13 hours  
ROUTE OF ADMINISTRATION : Oral 
DOSE     : 5mg, 20 mg 40 mg 
DOSAGE FORM   : Tablets 5mg, 20mg 40 mg 
USE     : Antihypertensive 
PHARMACOLOGY: 
Angiotensin II is formed from angiotensin I in a reaction catalyzed by 
angiotensin converting enzyme (ACE, kininase II).  Angiotensin II is the principal 
pressor agent of the rennin-angiotensin system, with effects that include 
vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac 
stimulation and renal reabsorption of sodium.  Olmesartan blocks the vasoconstrictor 
effects of angiotensin II by selectively blocking the binding of angiotensin II to the 
AT1 receptor in  vascular smooth muscle.  Its action is therefore independent of the 
pathways for angiotensin II synthesis.  Olmesartan has more than a 12, 500-fold 
greater affinity for the AT1 receptor than for the AT2 receptor.  
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PHARMACODYNAMICS: 
Olmesartan, a specific angiotensin II type I antagonist is used alone or with 
other antihypertensive agents to treat hypertensive agents to treat hypertension.  
Unlike the angiotensin receptor antagonist losartan, Olmesartan does not have an 
active metabolite or possess uricosuric effects.  Blockade of the angiotensin II 
receptor inhibits the negative regulatory feedback of angiotensin II on rennin 
secretion, but the resulting increased plasma rennin activity and circulating 
angiotensin II levels do not overcome the effect of Olmesartan on blood pressure. 
PHARMACOKINETICS: 
Olmesartan medoxomil is an ester prodrug that is hydrolysed during 
absorption from the gastrointestinal tract to the active form Olmesartan. The absolute 
bioavailability is about 26%. Peak plasma concentrations of Olmesartan occur about 
1 to 2 hours after oral doses. Olmesartan is at least 99% bound to plasma proteins. It 
is excreted in the urine and the bile as olmesartan; about 35 to 50% of the absorbed 
dose is excreted in the urine and the remainder in the bile. The terminal elimination 
half-life is between 10 and 15 hours.       
Distribution: 
The volume of distribution of Olmesartan is approximately 17 L. Olmesartan 
is highly bound to plasma proteins (99%) and does not penetrate red blood cells. The 
protein binding is constant at plasma Olmesartan concentrations well above the range 
achieved with recommended doses. 
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Metabolism and Excretion: 
Following the rapid and complete conversion of Olmesartan medoxomil to 
Olmesartan during absorption, there is virtually no further metabolism of 
Olmesartan. Total plasma clearance of Olmesartan is 1.3 L/h with a renal clearance 
of 0.6 L/h. 
Approximately 35% to 50% of the absorbed dose is recovered in urine while 
the remainder is eliminated in feces via the bile. 
ADVERSE EFFECTS: 
Dizziness, headache dose-related orthostatic hypotension. 
CONTRAINDICATIONS: 
Contraindicated in pregnant or intended to be pregnant and lactating mothers. 
DRUG INTERACTIONS: 
Drug-Drug Interactions: 
Drospirenone 
Increased risk of hyperkalemia. 
Tobramycin 
Increased risk of nephrotoxicity. 
Trandolapril 
May increase the adverse effects of Trandolapril. 
Trepostinil 
Additive hypotensive effect. 
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Diuretics: 
Patients on diuretics, and especially those in whom diuretic therapy 
was recently instituted, may occasionally experience an excessive reduction 
in blood pressure after initiation of therapy with olmesartan. The possibility 
of symptomatic hypotension with the use of olmesartan can be minimized by 
discontinuing the diuretic prior to initiation of treatment.   No drug interaction 
of clinical significance has been identified with thiazide diuretics. 
Agents Increasing Serum Potassium: 
Since olmesartan decreases the production of aldosterone, potassium-
sparing diuretics or potassium supplements should be given only for 
documented hypokalemia and with frequent monitoring of serum potassium. 
Potassium-containing salt substitutes should also be used with caution. 
Pravastatin: 
Olmesartan decreased the Cmax and AUC of pravastatin by 
approximately 25% and 21% respectively. Since there is a high degree of 
variability in the bioavailability of pravastatin, this finding is not considered 
to be clinically relevant. 
Warfarin: 
There was no effect on either the pharmacokinetics or 
pharmacodynamics of warfarin when coadministered with Olmesartan 
medoxomil) in healthy volunteers. 
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Digoxin: 
No pharmacokinetics or pharmacodynamics effects were reported 
when olmesartan was co-administered with digoxin in healthy volunteers. 
Antacids: 
The bioavailability of Olmesartan was not significantly altered when 
co-administered with antacids. 
Cytochrome P450 Enzyme Systems: 
Unlike some other angiotensin II receptor blockers, Olmesartan 
medoxomil is not metabolized by cytochrome P450 enzymes. Interactions 
with drugs that inhibit, induce or are metabolized by these enzymes are not 
expected. 
Lithium salts: 
As with other drugs which eliminate sodium, lithium clearance may 
be reduced in the presence of Olmesartan. Therefore, serum lithium levels 
should be monitored carefully if lithium salts are to be administered with 
Olmesartan medoxomil. Lithium generally should not be given with diuretics. 
Diuretic agents reduce the renal clearance of lithium and add a high risk of 
lithium toxicity. 
NSAID Agents including Selective Cyclooxygenase-2 Inhibitors(COX-2 
Inhibitors): 
In patients who are elderly, volume-depleted (including those on 
diuretic therapy), or with compromised renal function, co-administration of 
NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor 
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antagonists, including Olmesartan, may result in deterioration of renal 
function, including possible acute renal failure. These effects are usually 
reversible. Renal function should be monitored periodically in patients 
receiving Olmesartan and NSAID therapy. 
The antihypertensive effect of angiotensin II receptor antagonists, 
including Olmesartan may be attenuated by NSAIDs including selective 
COX-2 inhibitors. 
Drug-Food Interactions: 
Olmesartan may be administered with or without food as it does not 
affect the bioavailability. 
TOXICITY: 
Symptoms of overdose include dehydration, dry mouth, excessive thirst, 
muscle pain or cramps, nausea and vomiting, weakness, dizziness, low blood 
pressure and slow or irregular heartbeat. 
STORAGE AND STABILITY: 
15-30ºC  
(www.drugbank.com) 
(www.usfda.com) 
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CHAPTER VIII 
EXCIPIENTS PROFILE 
CARBOPOL 934 
Carbopol 934P  is cross-linked with allyl sucrose and is polymerized in 
solvent benzene. 
SYNONYMS: 
Acritamer acrylic acid polymer; Carbopol; carboxypolymethylene, 
polyacrylic acid; carboxyvinyl polymer; Pemulen; Ultrez. 
STRUCTURE: 
 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT: 
Carbomers are synthetic high-molecular-weight polymers of acrylic acid that 
are crosslinked with either allyl sucrose or allyl ethers of pentaerythritol. They 
contain between 56% and 68% of carboxylic acid (COOH) groups 104 400 g/mol for 
Carbopol 940 have been reported. 
STRUCTURAL FORMULA: 
Carbomer polymers are formed from repeating units of acrylic acid. The 
monomer unit is shown above. The polymer chains are crosslinked with allyl sucrose 
or allylpentaerythritol. 
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FUNCTIONAL CATEGORY: 
Bioadhesive; emulsifying agent; release-modifying agent; suspending agent; 
tablet binder; viscosity-increasing agent. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY: 
 Carbomers are mainly used in liquid or semisolid pharmaceutical 
formulations as suspending or viscosity-increasing agents. 
 Formulations include creams, gels, and ointments for use in ophthalmic, 
rectal, and topical preparations. 
 Controlled release in tablets. 
 Bioadhesion in buccal, ophthalmic, intestinal, nasal, vaginal and rectal 
applications. 
 Thickening at very low concentration to produce a wide range of viscosities  
and flow properties in topical, lotions, creams and gels. 
 Permanent suspensions of insoluble ingredients in oral suspensions and 
topical. 
Emulsifying agent    :  0.1–0.5 
Gelling agent    : 0.5–2.0 
Suspending agent   : 0.5–1.0 
Tablet binder    : 5.0–10.0 
Description   : Carbomers are white-colored,  
‘fluffy’, acidic, hygroscopic powders  
with a slight characteristic odor. 
Pharmacopeial Specifications : Carbomer 940 (0.5 w/v) — 40000– 
60000(a) 
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TYPICAL PROPERTIES: 
 Acidity/alkalinity 
 pH = 2.7–3.5 for a 0.5% w/v aqueous dispersion; 
 pH = 2.5–3.0 for a 1% w/v aqueous dispersion. 
 
Bulk Density     : 1.76–2.08 g/cm3 
Tapped Density    : 1.4 g/cm3 
Glass transition temperature : 100–105 o C 
Melting point    : Decomposition occurs within 30 
minutes  
at 260
o
C. 
Moisture content: 
 Normal water content is up to 2% w/w. However,   carbomers are 
hygroscopic and a typical equilibrium moisture content at 258C and 50% relative 
humidityis        8–10% w/w. The moisture content of a carbomer does not affect its 
thickening efficiency. (Hand book of Pharmaceutical Excipients by Raymond C. 
Rowe et .al., 2009) 
 
 
 
 
 
 
 
CHAPTER VIII                                                                      EXCIPIENTS PROFILE 
 
Olmesartan Buccal DDS Reg. NO. 261211306 Page 53 
 
CHITOSAN 
Chitosan is the term applied to deacetylated chitins in various stages of 
deacetylation and depolarization and it is therefore not easily defined in terms of its 
exact chemical composition. Partial deacetylation of chitin results in the production 
of chitosan which is a polysaccharide comprising copolymers of glucosamine and n-
acetylglucosamine. 
MOLECULAR WEIGHT: 
Chitosan is commercially available in several types and grades that vary in 
molecular weight between 10,000 and 1,000,000 and vary in degree of acetylation 
and viscosity. 
SYNONYMS: 
2-amino-2 –deoxy-(1,4)-ß-d-glucopyranan; deacetylated chitin; deacetyl 
chitin; ß-1,4- amino 2-deoxy-d-glucopyranosamine 
CHEMICAL NAME: 
 poly-ß-(1,4)-2-amino-2-deoxy-d-glucose 
DESCRIPTION: 
chitosan occurs as odorless,white or creamy whitepowder or flakes.fibre 
formation is quite common during precipitation and the chitosan may look ‘cotton 
like’. 
STRUCTURAL FORMULA: 
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FUNCTIONAL CATEGORY: 
Coating agent, disintegrant; film forming agent; mucoadhesive; tablet binder; 
viscosity-increasing agent 
TYPICAL PROPERTIES: 
Acidity: 
PH 4.0-6.0(1%w/v aqeous solution) 
Density: 
1.35-1.40 g/cm3 
Glass transition temperature: 
203
o
C 
MOISTURE CONTENT: 
Chitosan absorbs moisture from the atmosphere ,the amount of water absorbed 
depending upon the initial moisture content and the temperature and relative 
humidity of surrounding air. 
PARTICLE SIZE DISTRIBUTION: 
<30 mm 
SOLUBILITY: 
Sparingly soluble in water, practically, insoluble in ethanol95% and other 
organic solvents and neutral or alkali solutions at pH above 6.5. 
INCOMPATIBILITY: 
Chitosan is incompatible with strong oxidizing agents. 
SAFETY:  
Chitosan is investigated widely for use as an excipient in oral and other 
pharmaceutical formulation. It is biocompatible with both healthy and infected 
skin.chitosan has been shown to be biodegradable. 
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STABILITY AND STORAGE CONDITIONS: 
Chitosan powder is a stable material at room temperature, although it is 
hygroscopic after drying. Chitosan should be stored in tightly closed comtainer in a 
cool, dry place and it should be stored at a temperature of 2-80c 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: 
The suitability and performance of chitosan as a component of pharmaceutical 
formulations for drug delivery applications has been investigated in numerous 
studies. These include controlled drug delivery applications, used as a component of 
mucoadhesive dosage forms, rapid release dosage forms, improved peptide 
delivery.chitosan has been processed in to several pharmaceutical dosage forms, 
including gels, films, beads, microspheres, tablets and coating of liposomes.              
( Raymond et al., 2006). 
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HYDROXY PROPYL METHYL CELLULOSE 
 
SYNONYM: 
 Hypromellose. 
 Methocel 
STRUCTURE:(Hand book of Pharmaceutical Excipients. Pharmaceutical Press, 
London. 5
th
edtition) 
 
 where R is H, CH3, or CH3CH(OH)CH2 
EMPIRICAL FORMULA: 
 It is a partly O-methylated and O-(2-hydroxypropylated) cellulose.  It is 
available in several grades that vary in viscosity and extent of substitution. 
 
MOLECULAR WEIGHT: 
 10 000–1 500 000 Dalton 
DESCRIPTION: 
 Colour: white or creamy-white fibrous or granular powder. 
 Odour: odourless. 
 Taste: Tasteless. 
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Solubility: 
 Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in hot water, chloroform, ethanol (95%), and ether, but soluble in mixtures 
of ethanol and dichloromethane, mixtures of methanol and dichloromethane, and 
mixtures of water and alcohol. Certain grades of hypromellose are soluble in aqueous 
acetone solutions, mixtures of dichloromethane and propan-2-ol, and other organic 
solvents.  Some grades are swellable in ethanol. 
Density (bulk):   0.341 g/cm
3
 
Density (tapped):  0.557 g/cm
3
 
Density (true):1.326 g/cm
3
 
Melting point:  Browns at 190–2008C; chars at 225–2308C 
Glass transition temperature:  170–1808C. 
METHOD OF MANUFACTURE: 
 A purified form of cellulose, obtained from cotton linters or wood pulp, is 
reacted with sodium hydroxide solution to produce a swollen alkali cellulose that is 
chemically more reactive thanuntreated cellulose.  The alkali cellulose is then treated 
with chloromethane and propylene oxide to produce methyl hydroxypropyl ethers of 
cellulose.  The fibrous reaction product is then purified and ground to a fine, uniform 
powder or granules.  Hypromellose can then be exposed to anhydrous hydrogen 
chloride to induce depolymerization, thus producing low viscosity grades. 
Typical viscosity values for 2 % (w/v) aqueous solutions of different viscosity 
grades of hpmc at 20°c: 
Methocel K100 Premium LVEP : 100 
Methocel K4M Premium  : 4000 
Methocel K15M Premium  : 15000 
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Methocel K100M Premium  : 100 000 
Methocel E4M Premium  : 4000 
Methocel F50 Premium  : 50 
Methocel E10M Premium CR : 10 000 
Methocel E3 Premium LV  : 3 
Methocel E5 Premium LV  : 5 
Methocel E6 Premium LV   : 6 
Methocel E15 Premium LV  : 15 
Methocel E50 Premium LV  : 50 
Metolose 60SH   : 50, 4000, 10 000 
Metolose 65SH   : 50, 400, 1500, 4000 
Metolose 90SH   : 100, 400, 4000, 15 000  
 
STORAGE CONDITION: 
 It should be stored in a well-closed container, in a cool, dry place. 
HANDLING PRECAUTION: 
 Hypromellose dust may be irritant to the eyes and eye protection is 
recommended.  
 Excessive dust generation should be avoided to minimize the risks of 
explosion.  Hypromellose is combustible. 
 
(Hand book of Pharmaceutical Excipients by Raymond C. Rowe et.al., 2009) 
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XANTHAN GUM 
SYNONYMS: 
 Corn sugar gum.  
 Keltrol. 
 Rhodigel. 
 Vanzan NF. 
 Xantural. 
STRUCTURE: (Hand book of Pharmaceutical Excipients. Pharmaceutical Press, 
London. 5
th
edtition) 
 
EMPIRICAL FORMULA:  
 (C35H49O29) n  
 
MOLECULAR WEIGHT: 
2 x10
6
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DESCRIPTION: 
 Colour:White free flowing fine powder. 
 Odour :Oduorless. 
 Taste :Tasteless. 
Melting point: 
 Chars at 270
°
C. 
Solubility: 
 Practically insoluble in ethanol and ether;  
 Soluble in cold or warm water. 
 
Functional Category: 
 Stabilizing agent. 
 Suspending agent. 
 Viscosity-increasing agent 
Storage Conditions: 
 It should be stored in a well-closed container. 
Handling Precautions: 
 Observe normal precautions appropriate to the circumstances and quantity of 
material handled.  
 Eye protection and gloves are recommended. 
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CARBOXY METHYL CELLULOSE SODIUM 
Synonym:  
 Cellulose gum, Sodium cellulose glycolate 
Structure: 
 
Chemical formula: 
 
[C6H7O2(OH)x(OCH2COONa)y]n 
where 
n is the degree of polymerization 
x = 1.50 to 2.80 
y = 0.2 to 1.50 
x + y = 3.0 
(y = degree of substitution) 
 
Empirical formula:  
Sodium salt of poly carboxy methyl ether of cellulose  
Molecular weight:  
90 000 – 700 000 
Description:   
White to almost white, odorless, granular powder. 
Solubility: 
Practically insoluble in acetone, ethanol (95 %), ether and toluene. Easily 
dispersed in water at all temperatures forming clear, colloidal solutions.  
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Functional Category: 
Emulsifying agent (0.25 – 1.0 %), Gel forming agent (3.0 – 6.0 %),Tablet 
binder (1.0-6.0 %), Coating agent, Stabilizing  agent, Suspending agent, Tablet and 
Capsule disintegrant, viscosity increasing agent, water-absorbing agent. 
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LACTOSE 
SYNONYM: 
Lactopress Anhydrous. 
Lactosum. 
Milk sugar. 
STRUCTURE: (Hand book of Pharmaceutical Excipients. Pharmaceutical Press, 
London. 5
th
edtition) 
 
DESCRIPTION: 
White to off-white crystalline particles or powder. 
EMPIRICAL FORMULA: 
 C12H22O11 
MOLECULAR WEIGHT: 
 342.30 
SOLUBILITY: 
 Soluble in water,  
 Sparingly soluble in ethanol (95 %) and ether. 
FUNCTIONAL CATEGORY: 
 Binding agent. 
 Directly compressible excipient. 
 Lyopholization aid. 
 Tablet and capsule filler. 
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TALC 
SYNONYMS: 
 Powdered talc. 
 Purified French chalk. 
 Soapstone. 
STRUCTURE: (Hand book of Pharmaceutical Excipients. Pharmaceutical Press, 
London. 5
th
edtition) 
 
EMPIRICAL FORMULA: 
 Mg6(Si2O5)4(OH)4 
DESCRIPTION: 
 Appearance: Very fine, unctuous, crystalline powder. 
 Colour: White to grayish-white. 
 Odour: Odorless, impalpable.  
Solubility 
 Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Storage Conditions 
 It should be stored in a tightly closed container in a cool and dry place. 
Functional Category 
 Anti caking agent. 
 Glidant. 
 Lubricant. 
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MAGNESIUM STEARATE 
 
SYNONYMS: 
 Magnesium octadecanoate.  
 Octadecanoic acid.  
 Magnesium salt. 
 
STRUCTURE: (Hand book of Pharmaceutical Excipients. Pharmaceutical Press, 
London. 5
th
edtition) 
 
CHEMICAL NAME: 
 Octadecanoic acid magnesium salt 
 
EMPIRICAL FORMULA: 
 C36H70MgO4 
 
MOLECULAR WEIGHT: 
591.34 
 
DESCRIPTION: 
 It is a very fine powder. 
 
SOLUBILITY: 
 Insoluble in ethanol, ether and water. 
 Slightly soluble in warm benzene and warm ethanol 95%. 
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STABILITY AND STORAGE CONDITIONS: 
 It is stable and should be stored in a well closed container, in a cool, dry 
place. 
FUNCTIONAL CATEGORY: 
 Tablet and capsule lubricant. 
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CHAPTER IX 
EXPERIMENTAL PROTOCOL 
1. PREPARATION OF STANDARD CALIBRATION CURVE OF 
OLMESARTAN MEDOXOMIL 
a) Preparation of phosphate buffer pH 6.8: 
`A known volume of 50 ml of 0.2 M potassium dihydrogen phosphate is placed 
in a 200 ml volumetric flask.  22.4ml of sodium hydroxide is added and make up to 
the volume with distilled water. (Indian pharmacopoeia 2010) 
b) Determination of λmax of olmesartan medoxomil: 
Standard stock solution of olmesartan medoxomil is prepared by dissolving 
25mg of   drug in 25ml volumetric flask using methanol as solvent. From this stock 
solution, working standard solution of concentration 10μg/ml is prepared by 
appropriate dilutions using phosphate buffer pH 6.8. Working standard solution is 
scanned in the entire UV range (200-400nm) to determine the λ max. (Moynul Hasan 
et al., 2012) 
c) Preparation of calibration curve of olmesartan medoxomil: 
10 mg of standard olmesartan medoxomil is accurately weighed and 
transferred to 100 ml volumetric flask and is dissolved in methanol and diluted up to 
the mark with phosphate buffer pH 6.8 to produce a stock solution of 100 µg/ml. 
Appropriate amounts of this stock solutions are diluted with the same medium, which 
yield concentrations of 2-24 µg/ml. Absorbance is measured at λmax  using the 
phosphate buffer pH 6.8 as blank by U-V spectrophotometer and the calibration 
curve is plotted. (Moynul Hasan et al., 2012) 
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2. PREFORMULATION (COMPATABILITY) STUDIES 
The compatibility studies are carried out by infrared spectroscopy in order to 
evaluate the drug and polymer interactions. 
(a) Fourier Transform Infrared Spectroscopic studies (FTIR): 
Fourier transform infrared (FTIR) analysis is performed to interpret the 
interactions of pure drug with polymers and other ingredients. Infrared spectroscopy 
(Model-V-5300, JASCO, Japan) is performed for pure drug, pure polymers, physical 
mixture of drug and polymers and drug loaded buccal tablets. All the samples are 
mixed with KBr and vacuum packed to obtain pellets of the materials, which are 
analysed. All the spectra acquired scans between 400- 4000 cm
-1
 at a resolution of 
4cm
-1
. (Hiremath JG et al., 2009) 
3. FORMULATION OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE 
TABLETS 
METHOD: 
 
Direct compression method is employed to prepare buccal tablets of 
olmesartan medoxomil using, Carbopol 934, HPMC K15M, Xanthan Gum, Sodium 
carboxy methyl cellulose, Chitosan as mucoadhesive polymers. 
Mucoadhesive buccal tablet each containing 20mg of olmesartan medoxomil 
is prepared by direct compression method. The compositions of buccal tablet 
formulations are given in Table. All the ingredients are passed through a 60 mesh 
sieve. The required quantity of drug, various polymer mixtures and fillers are mixed 
thoroughly. The blend is lubricated with magnesium stearate for 3-5mins and talc 
was added as glidant.The blend is directly compressed (8 mm diameter, round flat 
faced punches) using single stroke tablet punching machine. All the tablets are stored 
in airtight containers for further study. (Raghavendra rao N.G et al., 2012). 
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4. EVALUATION OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE 
TABLET 
(I)Pre compressional evaluation of powder blend: 
(a) Bulk density (gm/ml): 
Bulk density denotes the total density of the material. It includes the true 
volume of interparticle spaces and intraparticle pores. The packing of particles is 
mainly responsible for bulk. Bulk density is the ratio between a given mass of 
powder and its bulk volume.  Apparent bulk density is determined by pouring the 
weighed granules into a graduated cylinder via funnel and measuring the volume.  
Density is calculated by using the formula, (Satyabrata Bhanja et al., 2013) 
 
Weight of the powder   W 
Bulk density =  ____________________ =  ___ 
Bulk volume of powder  V0 
 
(b) Tapped density (gm/ml) 
Aknown quantity of sample is transferred to a graduated cylinder and placed 
on tapped density apparatus and operated for a fixed number of taps (100).It is the 
ratio of weight of sample to tapped volume. (Satyabrata Bhanja et al., 2013) 
        Weight of the powder(W) 
Tapped density =      _____________________   
 
Tapped volume of powder(Vf) 
 
(c) Compressibility (or) Carr’s index: 
Based on the apparent bulk density and the tapped density, the percentage 
compressibility of the bulk drug is studied by using the following formula. 
 
Tapped Density - Bulk Density t - o 
Carr’s Index(%) = __________________________  = _____x 100 
Tapped Density   t 
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Compressibility Index (%) Type of Flow 
5-15% Excellent 
15-25% Good 
>25% Extremely poor 
(Satyabrata Bhanja et al., 2013) 
(d) Hausner's ratio 
Hausner’s ratio is defined as the ratio of tapped density to bulk density of the 
powders.  The hausner’s ratio is a number that is correlated to the flowability of a 
powder (or) granular material.  It is calculated by using the formula, 
 
t 
Hausner’s ratio = ________x 100 
o 
Where, 
o= Bulk density g/ml. 
t = Tapped density g/ml. 
The values less than 1.25 indicate good flow (=20% Carr), whereas greater 
than 1.25 indicates poor flow (=33% Carr) Between 1.25 and 1.5, added glidant 
normally improves flow. (Satyabrata Bhanja et al., 2013) 
(e) Angle of Repose ()  
Angle of Repose is defined as the maximum angle possible between the 
surface of the pile of powder and horizontal plane. Angle of repose has been used as 
indirect methods of quantifying powder flow ability, because of their relationship 
with inter particle cohesion. A static heap will slide when the angle of inclination is 
large enough to overcome frictional forces and stop when gravitational forces 
balance the forces. The sides of heap will make an angle with horizontal which is 
called angle of repose. (Satyabrata Bhanja et al., 2013) 
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Angle of Repose () =   tan -1 (h / r) 
Where, 
h = height of the heap. 
r = radius of the base of the heap. 
Angle of Repose ( ) Type of Flow 
<20 Excellent 
20 - 30 Good 
30 - 35 Moderate 
35 - 40 Poor 
>40 Very Poor 
 
(f) Drug Content of powder blend 
A known weight of (20mg) drug equivalent of powder blend is dissolved in 
sufficient quantity of methanol and the volume is made up to 100 ml with phosphate 
buffer pH 6.8. The solution is filtered and 5ml of filtrate is diluted to 100ml with 
phosphate buffer pH 6.8. The absorbance of the resulting solution is measured at      
max (257 nm) using UV spectrophotometer and the drug content was determined by 
using the formula, 
Sample absorbance 
Drug content =        ------------------------------ x 100 
Standard absorbance 
 
(II) Post compressional evaluation of buccal adhesive tablet 
(a) General appearance 
The formulated tablets are evaluated for general appearance viz., colour, 
shape, odour, appearance etc. 
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(b)Tablet dimension 
Thickness and diameter of five tablets randomly selected are measured using 
vernier calipers. The Pharmacopoeia states that the extent of deviation in a batch of 
tablet should not exceed the limit of ± 5% of  their determined standard values. 
Thickness of the tablet mainly depends upon the filling, physical properties of 
material to be compressed and compression force. (Satyabrata Bhanja et al., 2010) 
(c) Hardness test 
Tablets require a certain amount of strength or hardness and resistance to 
friability, to withstand mechanical shocks of handling in manufacture, packaging and 
shipping. The hardness of the tablets is determined using Monsanto hardness tester. It 
is expressed in kg/cm
2
. Five tablets are randomly picked from each formulation and 
the mean and standard deviation values are calculated and the results are shown in 
Table. (Satyabrata Bhanja et al., 2010) 
(d) Friability test 
Twenty tablets of the formulation are weighed and measured in a Roche type 
Friabilator (Shanghai Zhixin Instrument Co., Ltd.). The tablets were rotated at 25rpm 
for 4min, and the samples are then reweighed. The percentage friability was 
calculated using the equation: (Satyabrata Bhanja et al., 2010) 
   Initial Weight – Final Weight 
Percentage Friability = ------------------------------------ x100 
Initial Weight 
(e) Weight variation test 
Weight variation test is done by weighing 20 tablets individually, calculating 
the average weight and comparing the individual weight to the average as per I.P 
Specification.Not more than two tablets should deviate from the percentage as given 
in IP and none should deviate by more than twice that percentage. (Satyabrata Bhanja 
et al., 2010). 
CHAPTER IX                                                             EXPERIMENTAL PROTOCOL 
 
Olmesartan Buccal DDS Reg. No. 261211306 Page 73 
 
The following percentage deviation in Weight Variation is Shown in the table (IP 
2007) 
Average Weight of a Tablet Percent Deviation 
80mg or less ±10% 
More than 80mg but less than 
250mg 
±7.5% 
250mg or more ±5% 
 
(f) Estimation of drug content for tablets 
A known quantity of (20mg) drug equivalent of the powdered formulation is 
dissolved in sufficient amount of methanol, and the volume is made up to 100ml with 
phosphate buffer pH 6.8 and filtered. Pipette out 5ml of the filtrate and the volume is 
made up to 100ml with phosphate buffer pH 6.8. A known concentration (10µg/ml) 
solution is prepared from the above solution and analyzed for drug content.  Drug 
content is calculated by using the formula, 
  Sample absorbance 
Drug content =         ------------------------------ x 100 
Standard absorbance 
 
(g) Determination surface pH  
The surface pH of the buccal tablets is determined to investigate the chances 
of any side effects. As an acidic or alkaline pH may irritate the buccal mucosa, the 
surface pH should be close to neutral. The method used to determine surface pH of 
the formulation is according to reported method. In briefly, a combined glass 
electrode is used to measure the surface pH. The tablet is allowed to swell by keeping 
them in contact with distilled water (pH 6.8 ±0.01) for 2 hours and pH is noted by 
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bringing the electrode in contact with the surface of the formulations and allowing it 
to equilibrate for 1 minute. (Gaurav Kumar et al., 2011) 
(h) Ex-vivo mucoadhesive strength 
Bioadhesive strength of the buccal tablets is measured on modified physical 
balance used for determining the ex-vivo mucoadhesive strength of prepared buccal 
tablets. Fresh sheep buccal mucosa is obtained from a local slaughterhouse. The 
mucosal membrane is separated by removing underlying fat and loose tissues. The 
membrane is washed with distilled water and then with phosphate buffer pH 6.8 at 
37±1
0
c. Sheep buccal mucosa was tied to the glass petri dish, which was filled with 
phosphate buffer so that it just touched the mucosal surface. The buccal tablet is 
stuck to the lower side of a thread with cyanoacrylate adhesive. The two sides of the 
balance are made equally by keeping a 5 g weight on the right hand pan. Next, 
weight of 5 gm is removed from the right hand pan, which lowered the pan along 
with the tablet over the mucosa. The balance is kept in this position for 5 minutes 
contact time. Then weight is added slowly to the right hand pan until the tablet 
detached from the mucosal surface. (Muthukumaran M et al., 2012) 
(i)Swelling index studies 
The tablets of each formulation are weighed individually (W1) and placed 
separately in petri-dishes containing 15ml of phosphate buffer  (pH 6.8). At regular 
intervals (1, 2, 3, 4 and up to 12 hours) the tablets are removed from petri-dishes and 
excess water is removed carefully using filter paper. The swollen tablets are re-
weighed (W2); the swelling index of each formulation is calculated by using this 
formula. 
Swelling index (S.I) = W2-W1/W1 
Where, 
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W1= Initial Weight, W2= Final Weight (Suresh Kumar P et al., 2011) 
(j) In vitro release studies 
In vitro release studies are performed in USP type II paddle apparatus for 12 
hours.  The tablets are placed in the dissolution medium of 900 ml phosphate buffer 
pH 6.8 in the dissolution apparatus.  The paddle was rotated at 50 rpm maintained at 
37°C.  5 ml samples are withdrawn every 15 min for the first hour and every 30 min 
up to 12 hours. Sink conditions are maintained  after each sampling. Samples are 
analyzed at 257 nm using UV spectrophotometer.  The studies are done in triplicate. 
(Gaurav Kumar et al., 2011) 
(k) In vitro drug release kinetics studies 
In controlled or sustained release formulations the three most important rate 
controlling mechanisms are, 
 Diffusion 
 Swelling and 
 Erosion 
The In vitro release profiles obtained from the floating tablets are fitted to zero order, 
first order, Higuchi, Hixson Crowell, Korsemeyer&Peppas model kinetics, to find 
out the mechanism of drug release. (Agaiah Goud B et al., 2011) 
 
Release kinetics model Equation 
Zero order Qt = Q0 + K0 t 
First order In Qt = In Q0 + K0 t 
Hixson-Crowell Q0
1/3 – Qt1/3 + K t 
Higuchi Q = KH. t
1/2
 
Korsmeyer – Peppas Mt / M0 = a.tn 
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Fitness of release profiles to linear equations is assessed by comparing the 
coefficients of determination (r) values. 
For cylinder type of systems, 
n< 0.45  : Classical Fickian diffusion 
n=0.45 to 0.89 : Anomalous Non Fickian transport i.e. coupled  drug 
diffusionin the hydrated matrix and  polymer relaxation 
(Indicators of  both phenomenon) 
n=0.89   : Case II relaxational release transport - Zero order 
release (Polymer relaxation or swelling controlled 
systems) 
n> 0.8   : Super Case II transport. 
 
5.  SELECTION AND EVALUATION OF BEST FORMULATION 
The best formulation is selected based upon the results obtained from 
swelling index,      in vitro release studies, in vitro kinetic studies and in vitro 
mucoadhesive strength. 
(a)  Infrared spectroscopic studies (IR): 
 Best formulation is subjected to infrared spectroscopic studies (IR) as per the 
procedure already discussed in compatibility studies. 
(b) Differential scanning calorimetric studies (DSC): 
Differential scanning calorimetry is carried out to find out any incompatibility 
between       the drug and excipients used. 
(c)  Stability studies: 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, and enables 
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recommended storage conditions, re-test periods and shelf –lives to be established. 
Stability studies are carried out according to modified International conference on 
hormonisation (ICH) guidelines. The best formulation is kept in a stability chamber 
maintained at 40°C ± 5% and RH 75 % ±5% for 2 months.  Samples are analyzed for 
the drug content, in-vitro drug release and other physiochemical parameters 
periodically. (Bhaskar Umarji et al., 2012) 
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CHAPTER X 
RESULTS AND DISCUSSION 
1. PREPARATION OF STANDARD CALIBRATION CURVE OF 
OLMESARTAN MEDOXOMIL 
(a) Preparation of phosphate buffer pH 6.8 
The phosphate buffer pH 6.8 was prepared as per Indian Pharmacopoeia., 2010. 
(b) Determination of λmax of olmesartan medoxomil 
The absorption maximum (max) of the Olmesartan medoxomil was estimated 
by scanning the drug solution (10µg/ml) between 200-400 nm regions on UV 
spectrophotometer. The obtained spectrum showed that the absorption maximum 
(max) was 257nm in phosphate buffer pH 6.8 which was shown in Figure 2a. 
(c) Preparation of calibration curve of olmesartan medoxomil 
 The Standard Calibration curves of Olmesartan medoxomil were prepared by 
using phosphate buffer pH 6.8.  The absorbance was measured at max of 257nm.  
The correlation coefficient was found to be 0.9995. Olmesartan medoxomil obeys the 
beer’s law within the concentration range of (1-10µg/ml).  Calibration plot of 
Olmesartan in phosphate buffer pH 6.8 was shown in Table 1& Figure 2b. 
2. PREFORMULATION (COMPATABILITY) STUDIES 
(a) Infrared Spectroscopic studies (IR) 
 Infrared spectroscopic analysis was performed to check out the 
compatibility between the drug (Olmesartan medoxomil) and the mucoadhesive 
polymers (carbopol 934P, HPMC K15M, xanthan gum, chitosan and sodium carboxy 
methyl cellulose) used in the formulation of buccal adhesive tablets.  
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IR spectrum of the drug, polymers and the physical mixtures of drug with the 
polymers were shown in the Figure 3(a-l). Pure Olmesartan medoxomil spectra 
showed sharp characteristic peaks at 3291.28, 2928.38, 1832.14, 1707.78, 762.43 cm
-
1.
  All the above characteristic peaks appear in the spectra of all physical mixtures.  
It was found from the spectra that there was no major shifting as well as any 
loss of functional peaks in the spectra of drug, polymers and physical mixture of drug 
and  polymers. This clearly indicated that there was no interaction between the drug 
and the polymers. 
3. FORMULATION OF OLMESARTAN MEDOXOMIL BUCCAL 
ADHESIVE TABLETS 
 The individually weighed powder blends of each formulation were 
compressed in to tablets in a single punch tablet compressing machine. Each tablet 
contains 20mg of olmesartan medoxomil and mucoadhesive polymers such as 
carbopol 934P, HPMC K15M, CMC sodium, xanthan gum and chitosan in different 
ratios, mannitol, lactose, magnesium stearate and talc. The prepared buccal adhesive 
tablets were white in colour and round in shape. The ingredients for tablets of each 
formulation were shown in Table 2(A, B &C). All the prepared tablets were found 
to be good without chipping, capping and sticking. 
4) EVALUATION OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE 
TABLET 
I. Pre compression evaluation of powder blend 
 The powder blend of all the formulations was evaluated for the pre-
compression parameters such as Bulk Density, Tapped Density, Compressibility 
Index, Angle of Repose, and Percentage Drug Content.  
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(a) Bulk Density (gm/ml) 
 The bulk density of the powder blend was in the range of 0.32-0.35gm/ml, 
which indicates, that the powder blend was not bulky.  The results were shown in 
Table 3 (A & B) & Figure 4.   
(b) Tapped Density (gm/ml) 
 The tapped density of the powder blend was in the range of 0.43-0.45 gm/ml.  
The results were shown Table 3 (A & B) & Figure 5 which indicates smaller 
particles to occupy the voids between larger particles. 
(c) Compressibility Index (I)  
Compressibility index was found to be in between 19.44-23.25%, which 
indicates that the powder blend have the required flow property for compression.  
The results were shown in Table 3 (A & B) & figure 6. 
The normal range for Compressibility index (The science of dosage form design,, 
M.E. Aulton Third edition)  
S. No 
% Compressibility 
Range 
Flow Description 
1. 5-15 Excellent (Free flowing granules 
2. 12-16 
Good (Free flowing powdered 
granules 
3. 18-21 Fair (powdered granules) 
4. 23-28 Poor (Very fluid powder) 
5. 28-35 Poor (Fluid Cohesive powder) 
6. >40 Extremely poor (Cohesive powder) 
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(d) Hausner’s Ratio 
 The Hausner’s ratio of the powder blend was found to be in the range of 1.22-
1.30, which indicates good flow properties of powder blend.  The results were shown 
in Table 3 (A & B) & figure 7(Limit: 1.5-1.4) (The science of dosage form design, 
M.E. Aulton Third edition) 
(e) Angle of Repose ()  
 The angle of repose for the formulated powder blend was found to be in the 
range of    30
0
 05-32
0 
47, which indicates moderate flow properties of powder blend.  
The results were shown in Table 3 (A & B) & figure 8. 
(f) Drug content of powder blend  
 The percentage drug content for F1-F30 formulations were found to be in 
between 95.23-101.28%   ensured the uniformity of drug content.  The results were 
shown in Table 3 (A& B). From the above results it was concluded that the angle of 
repose (350) indicate moderate flow properties of the powder blend.  This was 
further supported by lower compressibility index value (25%) results in good to 
excellent flow properties.  Powder density and hardness were often interrelated 
properties. In addition, powder density may influence compressibility, tablet 
porosity, dissolution, and other properties.  All these results indicate that the powder 
blend of all the formulations possessed satisfactory flow properties. 
II. Post compression evaluation of buccal adhesive tablets 
 Tablets of different formulations were subjected to evaluation tests such as 
general appearance, tablet dimension, hardness, friability, weight variation, drug 
content, determination of surface pH, Ex-vivo mucoadhesive strength, swelling index 
studies, in-vitro release studies, in-vitro drug release kinetic studies. 
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(a) General appearance 
 The formulated tablets were white colour, flat and round shaped without any 
scoring on any sides.  All tablets were elegant in appearance.  
(b) Tablet dimension 
 The thickness and diameter of all the formulations were found to be in the 
range of 2.4-2.5 mm & 8mm, indicates that the tablets having uniform particle size 
distribution and no deformity.  The results were shown in Table 4 (A&B) 
(c) Hardness  
 The hardness of all the formulations were  found to be in the range of 6-7 
Kg/cm
2 
Which indicates good mechanical strength with an ability to withstand 
physical and chemical stress conditions while handling.  The results were shown in 
Table 4 (A & B) 
(d) Friability 
 The percentage friability of all formulations was found to be in between 0.23-
0.52%. The percentage friability was less than 1% in all the formulations (I.P.Limit: 
less than 1%), which indicates good mechanical resistance of the tablet.  The values 
of hardness test and percentage friability indicates good handling property of 
prepared tablet.  The results were shown in Table 4 (A & B) 
(e) Weight Variation  
 The weight variation test was performed according to the procedure given in 
the pharmacopoeia. All the formulated tablet (F1-F30) passes the weight variation 
test as the percentage weight variation was within the pharmacopoeia limits of ±7.5% 
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of the weight and hence all the formulations passes the weight variation within the 
acceptable limits as per I.P.  The results were shown in Table 4 (A & B) 
(f) Estimation of drug content for tablets 
 The percentage drug content of all formulations were within the range from 
97.61-100.18%, showed that the drug was uniformly distributed in all the 
formulations, hence the percentage drug content of all the formulations complies 
with official specifications as per U.S.P (Limit: not less than 90% and not more than 
110%)  The results were shown in Table 4 (A & B) 
(g) Determination of surface pH 
Surface pH of all the formulations F1 to F30 was found to be 6.22±0.08 to 
6.87±0.02, which is well within the limit of acceptable salivary pH range of 5.6 to 
7.9. Hence, it was concluded that all formulations may not produce any local 
irritation to the mucosal surface. The results are shown in Table 5 (A&B).  
(C) Ex -vivo mucoadhesive strength  
Mucoadhesive strength is the strength required to detach the tablet from the 
model   membrane. The strength of   mucoadhesion   is affected by various factors 
such as molecular weight of polymers, contact time with mucous membrane and 
swelling rate of the polymer. Adhesion was reported to be effected by hydration. 
Hydration of the mucoadhesive polymer is essential to initiate the mucoadhesive 
bonding process. Once the bond is formed, reduction in the rate of swelling takes 
place due to water uptake from the tissue surface, only prolong the association of the 
tablet with the mucosa. Removal of water from the underlying mucosa layer by the 
hydrating polymer may increase the cohesive forces of mucus; this plays vital role in 
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the establishment of an effective mucoadhesive bond. Mucoadhesive force depends 
on the viscosity and concentration of the polymer used (Gavaskar B. et .al.,2010 ). 
The results of mucoadhesive strength were shown in the Table 5 (A&B) & 
Figure 9A- 9F. Formulation containing carbopol 934P and HPMC K15M  (F1-F5), 
(2.5:1 ,1.5:1, 1:1, 1:1.5 & 1:2.5 ratio ) showed the mucoadhesive strength  of  
31.8gm, 30.1gm, 27.3gm, 24.4gm & 20.9gm respectively.  The mucoadhesive 
strength decreased in the following order  
             F1(2.5:1)>F2(1.5:1)>F3(1:1)>F4(1:1.5)>F5(1:2.5) 
Formulation containing carbopol 934P and xanthan gum (F6-F10), (2.5:1, 
1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the mucoadhesive strength of 31.2gm, 
29.4gm, 27.9gm, 23.7gm & 20.5gm respectively. The mucoadhesive strength 
decreased in the following order  
 F6(2.5:1)>F7(1.5:1)>F8(1:1)>F9(1:1.5)>F10(1:2.5) 
Formulation containing Carbapol 934 and CMC sodium (F11-F15), (2.5:1, 
1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the mucoadhesive strength of 30.4gm, 
27.3gm, 23.8gm, 20.5gm & 18.7gm respectively.  The mucoadhesive strength in 
decreasing order is as follows 
             F11(2.5:1)>F12(1.5:1)>F13(1:1)>F14(1:1.5)>F15(1:2.5) 
Formulation containing Carbopol 934P and chitosan (F16-F20), (2.5:1, 1.5:1, 
1:1, 1:1.5 & 1:2.5 ratio) showed the mucoadhesive strength of 21.9gm, 21.9 gm, 
21.7gm, 20.4gm & 19.7gm respectively. The mucoadhesive strength of decreasing 
order is as follows  
              F16(2.5:1)>F17(1.5:1)>F18(1:1)>F19(1:1.5)>F20(1:2.5) 
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Formulation containing HPMC K15M and CMC sodium (F21-F25), (2.5:1, 
1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the mucoadhesive strength of 19.7gm, 18.9 
gm, 18.6gm, 21.5gm & 21.4gm respectively. The mucoadhesive strength of 
decreasing order is as follows  
              F21(2.5:1)>F22(1.5:1)>F23(1:1)>F24(1:1.5)>F25(1:2.5) 
Formulation containing HPMC K15M and xanthan gum (F26-F30), (2.5:1 
,1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the mucoadhesive strength of 21.5gm, 21.4 
gm, 20.1gm, 19.6gm & 19.1gm respectively. The mucoadhesive strength of 
decreasing order is as follows  
             F26(2.5:1)>F27(1.5:1)>F28(1:1)>F29(1:1.5)>F30(1:2.5) 
Buccal tablets containing carbopol 934P and HPMC K15M in the ratio of 
2.5:1(F1) exhibited the highest bioadhesive strength (31.8±.35gm). The tablets 
containing a higher proportion of carbopol 934P showed good mucoadhesive 
strength. Mucoadhesive strength decreases with decrease in the carbopol 
concentration. The higher bioadhesive strength  of carbopol may be due to the 
formation of secondary bioadhesion bonds with mucin and interpenetration of the 
polymer chains in the interfacial region, while the other polymers only undergo 
superficial bioadhesion. So mucoadhesive strength decreases with decreasing the 
carbopol 934P ratio. (Hiremath JG et al., 2009). 
(h) Swelling index studies 
Appropriate swelling behaviour of a buccal adhesive system is an essential 
property for uniform and controlled release of drug and effective mucoadhesion. 
Swelling index was calculated with respect to time. As time increased, the SI was 
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also increased, because of the weight gain by tablet is increased proportionally with 
rate of hydration. 
 Swelling study was performed on all the batches (F1-F30) for 12 hours. The 
results of the swelling index(SI) were given in the Table 6 (A& B) & Figure10A-
10F. Swelling plays an important role in mucoadhesion and drug dissolution of 
buccal tablets. 
 The formulations containing carbopol 934P and HPMC K15M (F1-F5),( 
2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio)showed the swelling index of 249.6%, 228.1%, 
197.1%, 177%, &133% at the end of 12 hours.  The rate of decrease of SI was found 
to be in this manner, F1> F2 > F3 > F4> F5 
 The formulations containing carbopol 934P and xanthan gum (F6-F10),( 
2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the swelling index of 246.1%, 241%, 
245.3%, 221.7% & 192.1 % at the end of 12 hours.  The rate of decrease of SI was 
found to be in this manner, F6> F7 > F8 > F9> F10      
 The formulations containing carbopol 934P and CMC sodium (F11-F15), 
(2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the swelling index of 238.5%, 225%, 
184.1%, 128.8%, & 104.5% at the end of 12 hours. The rate of decrease of SI was 
found to be in this manner, F11> F12 > F13 > F14> F15 
The formulations containing carbopol 934P and chitosan combination(F16-
F20), (2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the swelling index of 239.1%, 
230.2%, 178.9%, 169.4%, &115.6% at the end of 12 hours.  The rate of decrease of 
SI was found to be in this manner, F16> F17 > F18 > F19> F20 
The formulations containing HPMC K15M and CMC sodium 
combination(F21-F25), (2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio)showed the swelling 
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index of 121.6%, 119.5%, 115.1%, 121.2%, &113.4% at the end of 12 hours.  The 
rate of decrease of SI was found to be in this manner, F21> F22 > F23 > F24> F25 
The formulations containing HPMC K15M and Xanthan gum 
combination(F26-F30), (2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the swelling 
index of 127.5%, 135.3%, 132.1%, 123.7%, &126.9% at the end of 12 hours.  The 
rate of decrease of SI was found to be in this manner, F26> F27 > F28 > F29> F30 
In this study, the higher swelling index was found for tablets of formulation 1 
(F1) containing carbopol 934P and HPMC K15M in the ratio of 2.5:1. Amount of 
carbopol plays an important role in swelling of the matrix and leads to the drug 
diffusion.  The hydrophilicity of carbopol 934P is greater than other polymers used, 
so it swells faster (Anand Padole et al., 2012). In all these formulations, it was 
observed that, the SI decreased on decreasing the carbopol 934P polymer 
concentration. 
Hence, it can be concluded from the results that linear relationship exists 
between swelling process and bioadhesion of polymer. (Dalvadi HP et al., 2010). 
(i)  In vitro release studies 
The in vitro release studies showed that the release profiles of different 
formulations varied according to the type and ratios of polymers. The results of in 
vitro drug release studies of all formulations shown in Table 7A to 7F & Figure 
11A-11F. 
 The formulations containing carbopol 934P and HPMC K15M (F1-F5),( 
2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio)showed the drug release of 249.6%, 228.1%, 
197.1%, 177%, &133% at the end of 12 hours.  The rate of decrease of drug release 
was found to be in this manner, F1> F2 > F3 > F4> F5 
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 The formulations containing carbopol 934P and xanthan gum (F6-F10),         
( 2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the drug release  of 246.1%, 241%, 
245.3%, 221.7% & 192.1 % at the end of 12 hours.  The rate of decrease of drug 
release was found to be in this manner, F6> F7 > F8 > F9> F10      
 The formulations containing carbopol 934P and CMC sodium (F11-F15), 
(2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the drug release of 238.5%, 225%, 
184.1%, 128.8%, & 104.5% at the end of 12 hours. The rate of decrease of drug 
release was found to be in this manner, F11> F12 > F13 > F14> F15 
The formulations containing carbopol 934P and chitosan combination(F16-
F20), (2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the drug release of 239.1%, 
230.2%, 178.9%, 169.4%, &115.6% at the end of 12 hours.  The rate of decrease of 
drug release was found to be in this manner, F16> F17 > F18 > F19> F20 
The formulations containing HPMC K15M and CMC sodium combination 
(F21-F25), (2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio)showed the drug release of 121.6%, 
119.5%, 115.1%, 121.2%, &113.4% at the end of 12 hours.  The rate of decrease of 
drug release was found to be in this manner, F21> F22 > F23 > F24> F25 
The formulations containing HPMC K15M and Xanthan gum 
combination(F26-F30), (2.5:1, 1.5:1, 1:1, 1:1.5 & 1:2.5 ratio) showed the drug 
release of 127.5%, 135.3%, 132.1%, 123.7%, &126.9% at the end of 12 hours.  The 
rate of decrease of drug release was found to be in this manner, F26> F27 > F28 > 
F29> F30 
In-vitro dissolution studies clearly indicated that the formulation 1(F1) 
containing carbopol 934P and HPMC K15M in the ratio of 2.5:1 showed higher drug 
release in a controlled manner as compared to other formulations. The release of 
CHAPTER X                                                               RESULTS AND DISCUSSION 
 
Olmesartan Buccal DDS Reg. No. 261211306 Page 89 
 
olmesartan medoxomil increased with increasing the amount of carbopol 934P. 
Carbopol 934P is more hydrophilic than HPMC K15M and other polymers; it swells 
rapidly, therefore decrease in carbopol content may delay the drug release. Drug 
release rate was increased with increasing amount of hydrophilic polymer. Another 
explanation includes high water uptake which leads to considerable swelling of 
polymer and causes drug to diffuse out from polymer matrix. Moreover the 
hydrophilic polymers would leach out and hence creates more pores and channels for 
drug to diffuse out from the device. 
 F1 was found to be best formulation on the basis of in vitro drug release, 
swelling index and mucoadhesive strength. It showed maximum drug release profile 
in a controlled manner at the end of 12 hours. (Hiremath JG et al., 2009). 
(F)    In vitro drug release kinetic studies 
To characterize  the release mechanism of olmesartan medoxomil from 
buccal adhesive tablets, the in vitro release data was subjected to various kinetic 
models (zero order, first order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas 
model).  The release kinetic data for all the formulations were shown in the Table 8 
(A&B).  
 The kinetic studies of all the formulations showed that zero order plots were 
fairly linear as indicated by their high regression values.  Therefore it was 
ascertained that the drug release from all the formulation followed zero order kinetics 
(r 
2
=0.995 to 0.999). Formulation1 (F1) showed the closest linearity to unity 
(r=0.999) as shown in Figure 12A. 
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All formulations exhibited a very good linearity for the Korsmeyer- peppas 
model. The values of n (diffusion exponent) were estimated by linear regression of 
log cumulative % drug release Vs log time (t) of different formulations.  
The obtained values of n lie between 0.5 to 1.0 in all the formulations 
exhibiting a non- fickian release behaviour controlled by combination of diffusion 
and chain relaxation mechanism. Fitness of the data to Korsemeyer and peppas plots 
resulted in a linear graph with regression values close to 1 (r
2
= 0.990-0.999). (Yadav 
Deepak R et al., 2011). 
5. SELECTION AND  EVALUATION OF BEST FORMULATION 
The best formulation is selected based upon the results obtained from 
swelling index,      in vitro release studies, in vitro kinetic studies and in vitro 
mucoadhesive strength. 
(a) Fourier transform infrared spectroscopic studies (FTIR) 
IR spectrum of the best formulation F1(carbopol and HPMC K15M in 2.5:1 
ratio)was recorded.  Pure olmesartan  spectra showed sharp characteristic peaks at 
3291.28, 2928.38, 1832.14, 1707.78, 762.43 cm
-1.
 (Figure 3 (a-l)).  All the above 
characteristic peaks appear in the IR spectrum of best formulation which indicates 
that there was no modification or interaction between drug and polymers. 
(b) Differential Scanning Calorimetric (DSC) Studies 
DSC thermogram of the best formulation F1 (carbopol and HPMC K15M in 
2.5:1 ratio) was recorded. Pure olmesartan exhibits a sharp endothermic peak at 
184.67
0
C (Figure 3m). An endothermic peak corresponding to the melting point of 
pure drug was prominent in best formulation (F1) (Figure 3t), which suggested 
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clearly that there was no interaction between the drug and the polymers and the drug 
was existed in its unchanged form. 
(b) Stability Studies 
 Optimized formulation F1 was subjected to stability studies at 40°C±5% and 
RH 75%±5% RH. The results showed no significant change in the physical 
appearance, and in vitro release studies during storage. Thus it was found that the 
buccal adhesive tablets of olmesartan medoxomil were stable under these storage 
conditions. The results are shown in the Table 9.  (Bhaskar Umarji et al., 2012). 
  
 
 
 
 
 
 
 
 
 
 
TABLES  
  
TABLE 1 CALIBRATION OF OLMESARTAN MEDOXOMIL USING 
PHOSPHATE BUFFER pH 6.8 
n=3*                                                                   r=0.9995 
 
 
S.No. 
CONCENTRATION  
(µg/ml) 
ABSORBANCE AT 257nm 
(±SD) 
1 2 0.113±0.008 
2 4 0.227±0.013 
3 6 0.335±0.014 
4 8 0.455±0.014 
5 10 0.545±0.011 
6 12 0.672±0.021 
7 14 0.777±0.017 
8 16 0.891±0.021 
9 18 0.973±0.030 
10 20 1.098±0.021 
11 22 1.204±0.021 
12 24 1.345±0.040 
  
TABLE 2A FORMULATION OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE 
TABLETS (F1-F10) 
S.NO Ingredients 
Quantity (mg) for 1 tablets (Total weight 150mg) 
F1 F2      F3 F4 F5 F6 F7 F8 F9 F10 
1 
Olmesartan 
medoxomil 20 20 20 20 20 20 20 20 20 20 
2 Carbopol  934P 70 60 50 40 30 70 60 50 40 30 
3 HPMC K15M 30 40 50 60 70 - - - - - 
4 Xanthan gum - - - - - - - - - - 
5 
Sodium 
carboxymethyl 
cellulose - - - - - - - - - - 
6 Chitosan - - - - - - - - - - 
7 Lactose 15 15 15 15 15 15 15 15 15 15 
8 Mannitol 10 10 10 10 10 10 10 10 10 10 
 
       9 Magnesium 2 2 2 2 2 2 2 2 2 2 
     10 Talc 3 3 3 3 3 3 3 3 3 3 
             
  
TABLE 2B FORMULATION OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE 
TABLETS (F11-F20) 
S.NO Ingredients 
Quantity (mg) for 1 tablets (Total weight 150mg) 
F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 
1 
Olmesartan 
medoxomil 20 20 20 20 20 20 20 20 20 20 
2 Carbopol  934P 70 60 50 40 30 70 60 50 40 30 
3 HPMC K15M - - - - - - - - - - 
4 Xanthan gum - - - - - - - - - - 
5 
Sodium 
carboxymethyl 
cellulose 30 40 50 60 70 - - - - - 
6 Chitosan - - - - - 30 40 50 60 70 
7 Lactose 15 15 15 15 15 15 15 15 15 15 
8 Mannitol 10 10 10 10 10 10 10 10 10 10 
 
       9 Magnesium 2 2 2 2 2 2 2 2 2 2 
     10 Talc 3 3 3 3 3 3 3 3 3 3 
             
  
TABLE 2C FORMULATION OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE 
TABLETS (F21-F30) 
S.NO Ingredients 
Quantity (mg) for 1 tablets (Total weight 150mg) 
F21 F22 F23 F24 F25 F26 F27 F28 F29 F30 
1 
Olmesartan 
medoxomil 20 20 20 20 20 20 20 20 20 20 
2 Carbopol  934P - - - - - - - - - - 
3 HPMC K15M 70 60 50 40 30 70 60 50 40 30 
4 Xanthan gum - - - - - 30 40 50 60 70 
5 
Sodium 
carboxymethyl 
cellulose 30 40 50 60 70 - - - - - 
6 Chitosan - - - - - - - - - - 
7 Lactose 15 15 15 15 15 15 15 15 15 15 
8 Mannitol 10 10 10 10 10 10 10 10 10 10 
 
       9 Magnesium 2 2 2 2 2 2 2 2 2 2 
     10 Talc 3 3 3 3 3 3 3 3 3 3 
            
  
TABLE 3A PRECOMPRESSIONAL EVALUATION OF POWER BLEND (F 1- F15) 
Formulation 
code 
Bulk density 
(g/ml) 
Tapped 
density 
(g/ml) 
Carr’s index 
(%) 
Hausner 
ratio 
Angle of repose 
(
0
) 
Drug content 
(%) 
F1 0.33±.003 0.44±.009 23±.31 1.29±.005 32.03±0.0 97.9±0.02 
F2 0.32±.001 0.43±.006 23.2±.74 1.3±0.02 31.62±0.02 96.7±.01 
F3 0.35±.001 0.45±.012 22.7±2.01 1.29±0.03 31.78±0.03 99.4±1.01 
F4 0.35±.001 0.43±.003 19.4±0.47 1.24±0.01 32.12±0.03 99.2±.07 
F5 0.33±0.03 0.43±.001 20.9±1.5 1.22±0.02 30.87±0.01 98.3±.032 
F6 0.33±.005 0.44±.009 22.6±1.4 1.29±0.02 30.87±0.02 98.4±.11 
F7 0.33±.007 0.43±.009 22.7±1.5 1.3±0.02 31.29±0.02 99.7±.04 
F8 0.33±0.01 0.44±0 22.8±1.4 1.28±0.02 31.43±0.02 99.1±.007 
F9 0.34±.008 0.43±.002 22.3±.42 1.28±0.05 31.32±0.02 98.3±.004 
F10 0.33±.004 0.43±0 22±1.05 1.28±0.01 31.1±0 98.9±.02 
F11 0.33±.003 0.43±0 21.78±0.74 1.27±0.01 31±0.01 97.8±.004 
F12 0.34±.004 0.45±.012 22.68±0.93 1.3±.005 32.19±0.05 98.6±.012 
F13 0.34±.002 0.43±.003 19.44±0.47 1.28±.005 32.47±0.01 99.2±.011 
F14 0.35±0.7 0.43±.001 20.91±1.05 1.27±0.01 32.28±0.01 97.9±.003 
F15 0.34±.004 0.44±.009 22.63±1.04 1.28±0.01 32.26±0.01 99.2±.002 
  
TABLE 3B TABLE PRECOMPRESSIONAL EVALUATION OF POWER BLEND (F16- F30) 
Formulation 
code 
 
Bulk density 
(g/ml) 
Tapped 
density 
(g/ml) 
Carr’s index 
(%) 
Hausner ratio 
Angle of repose 
(
0
) 
Drug content 
(%) 
F16 0.33±0.01 0.43±.009 22.7±1.5 1.29±0.005 31.5±1.2 99.45±.001 
F17 0.33±.001 0.44±0 22.81±.16 1.27±0.01 31.2±.81 99.08±.07 
F18 0.32±.03 0.43±.002 22.33±.42 1.26±.005 32.29±.24 99.2±.002 
F19 0.35±.002 0.43±0 22.09±1.05 1.27±0.01 31.27±.95 99.8±.001 
F20 0.35±.001 0.43±0 21.78±.74 1.26±0 30.57±.27 98.9±0.02 
F21 0.33±.003 0.43±.001 21.53±.92 1.24±0.01 30.8±.58 100.3±.005 
F22 0.33±.007 0.43±.009 21.44±1.04 1.22±0.02 30.96±.39 98.9±0.04 
F23 0.33±.011 0.44±0 22.04±0.09 1.29±0.02 30.8±.58 100.7±0.011 
F24 0.33±.003 0.43±.002 21.01±0.55 1.29±0.02 30.96±.39 99.1±.006 
F25 0.33±.001 0.43±0 22.33±0.42 1.3±.005 30.5±.24 101.1±.007 
F26 0.33±.008 0.43±0 22.09±1.05 1.28±.017 30.8±.58 99.2±0.04 
F27 0.32±.011 0.45±.012 21.78±0.74 1.28±.011 31.27±.95 99.8±0.09 
F28 0.34±.004 0.43±.003 22.68±0.93 1.27±.005 31.66±.42 99.3±0.006 
F29 0.33±.003 0.43±.001 19.44±0.47 1.3±.005 31.19±.39 97.9±0.002 
F30 0.33±.005 0.44±.005 20.91±0.59 1.28±.005 30.9±.59 99.2±0.011 
 
TABLE 4A POST COMPRESSION EVALUATION OF BUCCAL ADHESIVE 
TABLETS (F1-F15) 
Formulation 
Code 
Hardness 
(kg/cm
3
) 
Thickness 
(mm) 
Diameter 
(mm) 
Friability 
(%) 
Average 
Weight 
(mg 
±7.5%)* 
Drug 
Content 
(%) ± 
S.D* 
F1 6 2.4 8 0.4 151.27 99.10±0.64 
F2 6 2.4 8 0.36 152.12 99.02±0.21 
F3 6 2.4 8 0.23 151.4 99.63±0.12 
F4 6 2.4 8 0.3 152 98.89±0.07 
F5 7 2.3 8 0.4 152.25 98.17±0.11 
F6 6 2.4 8 0.36 152.4 98.90±0.05 
F7 6 2.4 8 0.58 152.7 98.72±0.07 
F8 6 2.4 8 0.48 153.8 98.90±0.05 
F9 6 2.4 8 0.36 153.1 99.82±0.64 
F10 7 2.3 8 0.3 153.1 98.17±0.07 
F11 6 2.4 8 0.3 153.3 99.27±0.11 
F12 6 2.4 8 0.46 153.8 98.90±0.05 
F13 7 2.3 8 0.36 153.5 99.27±0.06 
F14 6 2.4 8 0.42 153.8 99.08±0.11 
F15 6 2.4 8 0.52 153.8 99.82±0.05 
n=3* 
TABLE 4B POST COMPRESSION EVALUATION OF BUCCAL ADHESIVE 
TABLETS (F16-F30) 
Formulation 
Code 
Hardness 
(kg/cm
3
) 
Thickness 
(mm) 
Diameter 
(mm) 
Friability 
(%) 
Average 
Weight 
(mg 
±7.5%)* 
Drug 
Content 
(%) ± 
S.D* 
F16 6 2.4 8 0.46 152.8 98.89±0.07 
F17 7 2.3 8 0.43 152.3 98.72±0.15 
F18 6 2.4 8 0.42 153.9 99.63±0.08 
F19 6 2.4 8 0.43 151.2 99.08±0.15 
F20 6 2.4 8 0.42 152.3 97.61±0.07 
F21 7 2.3 8 0.43 152.4 97.98±0.12 
F22 6 2.4 8 0.33 151.9 98.35±0.14 
F23 6 2.4 8 0.48 152.1 98.90±0.14 
F24 6 2.4 8 0.36 152.1 98.89±0.03 
F25 6 2.4 8 0.23 153.8 98.35±0.14 
F26 7 2.3 8 0.39 152.4 98.72±0.16 
F27 6 2.4 8 0.36 153.3 98.72±0.04 
F28 6 2.4 8 0.4 151.8 99.27±0.14 
F29 6 2.4 8 0.45 152.4 98.35±0.09 
F30 7 2.3 8 0.3 151.9 99.08±0.13 
n=3* 
 
 
 
 
TABLE 5A MUCOADHESIVE STRENGTH AND SURFACE pH OF 
OLMESARTAN BUCCAL ADHESIVE TABLETS 
Formulation code 
Mucoadhesive 
strength(gm) 
Surface pH 
F1 31.8±0.35 6.67±0.12 
F2 30.1±0.30 6.62±0.19 
F3 27.3±0.85 6.55±0.18 
F4 24.4±0.26 6.81±0.08 
F5 20.9±0.36 6.59±0.11 
F6 31.2±0.37 6.52±0.15 
F7 29.4±0.67 6.7±0.10 
F8 27.9±0.21 6.7±0.18 
F9 23.7±0.37 6.54±0.24 
F10 20.5±0.20 6.62±0.27 
F11 30.4±0.36 6.68±0.49 
F12 27.3±0.26 6.81±0.12 
F13 23.8±0.26 6.77±0.24 
F14 20.5±40 6.69±0.19 
F15 18.7±0.30 6.73±0.07 
n=3* 
 
 
 
 
 
TABLE 5B MUCOADHESIVE STRENGTH AND SURFACE pH OF 
OLMESARTAN BUCCAL ADHESIVE TABLETS 
Formulation code 
Mucoadhesive 
strength(gm) 
Surface pH 
F16 21.9±1.25 6.61±0.14 
F17 21.9±1.05 6.74±0.15 
F18 21.7±1.17 6.67±0.12 
F19 20.4±0.92 6.85±0.05 
F20 19.7±0.47 6.57±0.18 
F21 19.7±0.25 6.4±0.13 
F22 19.5±0.40 6.46±0.07 
F23 19.5±0.75 6.48±0.04 
F24 18.9±0.30 6.65±0.11 
F25 18.6±0.11 6.57±0.18 
F26 21.5±1.12 6.66±0.11 
F27 21.4±0.52 6.59±0.22 
F28 20.0±0.25 6.82±0.04 
F29 19.6±0.40 6.54±0.26 
F30 19.1±0.72 6.58±0.13 
n=3*
  
TABLE 6A SWELLING INDEX OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE TABLETS (F1-F15) 
Formulation 
code 
Time in hours 
1 2 3 4 5 6 7 8 9 10 11 12 
F1 36.18 44.4 64 84.3 102.6 127.1 148.3 172.5 195.4 212.5 233.3 249.6 
F2 31.56 37.25 54.9 75.2 88.9 113.1 136 156.2 178.4 195 212.4 228.1 
F3 38.02 47.06 58.8 73.2 81.7 104 120.5 135.4 152.3 164.6 182.8 197.1 
F4 30.14 44.3 56.9 74.3 90.8 110 125.6 150 164.5 183.5 181.6 177 
F5 21.1 40.5 48.3 64.1 81.7 98.1 118.9 135.3 138.6 141.8 133.9 133 
F6 24 49.4 69.4 88.3 109 127.2 145.9 171.8 195.2 211.8 228.5 246.1 
F7 19.7 39.6 54.5 78.5 98 118.8 139.6 161 188.9 209.1 231.2 241 
F8 21.7 43.4 54.6 71.7 90.8 113.8 138.2 160.5 177.6 201.3 222.4 245.3 
F9 12 31.6 45.4 61.2 71.1 94.7 115.8 141.4 159.9 182.9 199.3 221.7 
F10 14.4 26.8 37.3 50.3 66.7 81.7 96.1 111.1 128.8 149.7 167.9 192.1 
F11 18 37.9 56.2 73.2 93.5 115.7 133.9 154.9 174.5 197.4 216.3 238.5 
F12 19 40.5 50.3 68.6 83 105.9 123.5 145.1 163.4 186.3 204 225 
F13 25.2 39.1 50.3 65.6 81.5 98 111.9 128.5 138.4 153.6 164.9 184.1 
F14 17.6 24.2 40.5 55.6 69.9 84.3 98 111.8 129.4 135.3 131.4 128.8 
F15 18.8 29.9 43.5 59.1 68.8 83.8 93.5 100.6 118.8 124 115.6 104.5 
 
  
TABLE 6B SWELLING INDEX OF OLMESARTAN MEDOXOMIL BUCCAL ADHESIVE TABLETS (F16-F30) 
Formulation 
code 
Time in hours 
1 2 3 4 5 6 7 8 9 10 11 12 
F16 28.3 50 74.3 97.4 117.1 134.8 156.6 173 189.4 207.8 225.6 239.1 
F17 29.6 48 73 94.1 115.7 130.3 150.6 166.4 184.2 199.3 215.7 230.2 
F18 24.1 48.3 68.6 89.5 100.1 115.4 121.3 140.6 153.8 158.2 167.6 178.9 
F19 23.7 47.3 65.7 85.4 96.5 109 119.2 134.5 146.4 149.8 156.5 169.4 
F20 26.1 37.2 50.3 62 71.2 83 94.1 107.8 115.6 114.3 118.3 115.6 
F21 19.6 35.9 47.1 65.4 79.7 92.8 113.7 119 128.1 118.9 122.2 121.6 
F22 20.9 34 45.8 63.4 77.8 89.5 105.9 115.7 120.9 119.5 122.2 119.5 
F23 20.9 37.3 49.9 64.3 75.4 85.8 95.6 108.6 120.3 118.4 115.1 115.1 
F24 25.8 42.4 55.6 65.6 78.8 92.7 101.9 108.6 121.9 118.5 123.8 121.2 
F25 23.8 40.3 64.7 76.5 89.7 100.9 107.5 117.4 122.7 122.7 117.4 113.4 
F26 22.2 41.8 49.1 66.7 79.7 96.1 115.7 132 141.8 141.8 135.3 127.5 
F27 24.2 43.8 52.9 69.8 81.7 99.3 112.5 128.8 141.8 138.6 141.8 135.3 
F28 22.2 33.9 47.1 62.1 69.9 83 99.3 12.4 109.2 115.7 133.9 132.1 
F29 25 33.6 44.7 56.6 71.1 80.9 90.8 107.2 117.1 113.8 117.1 123.7 
F30 26.3 36.8 44.7 56.6 67.8 84.2 96.1 103.9 113.8 123 120.4 126.9 
TABLE 7A INVITRO RELEASE DATA OF OLMESARTAN MEDOXOMIL 
BUCCAL ADHESIVE TABLETS (CARBOPOL: HPMC K15M)   (F1-F5) 
Time 
In 
Hours 
 
Cumulative % Drug Release ±SD (n=3*) 
F1(2.5:1) 
(%) 
F2(1.5:1) 
(%) 
F3(1:1) 
(%) 
F4(1:1.5) 
(%) 
F5(1:2.5) 
(%) 
0.25 2.53±0.49 2.6±0.50 2.52±0.50 1.98±0.41 1.65±0.24 
0.5 5.05±0.50 5.01±0.32 4.67±0.78 3.63±0.68 3.14±0.25 
0.75 7.1±0.93 7.63±0.19 6.77±2.00 6±1.27 5.01±0.33 
1 10.13±1.59 8±0.28 9.1±1.85 8.03±1.02 7.06±0.60 
1.5 13.96±0.86 10.83±0.86 12.59±2.15 11.24±0.72 9.61±0.25 
2 16.72±1.19 13.56±0.33 15.39±2.37 14.55±0.24 12.88±0.33 
2.5 19.98±0.98 16.21±0.91 18.64±1.88 17.9±0.41 16.06±0.59 
3 22.98±1.51 20.26±0.49 22.12±1.88 20.73±0.23 18.79±0.40 
3.5 26.38±0.26 24.58±0.34 25.3±2.30 23.46±1.01 21.93±0.32 
4 30.29±1.68 30.04±0.16 28.61±2.30 26.65±0.89 24.95±0.09 
4.5 33.13±1.17 33.15±0.84 32.21±1.77 29.74±0.24 27.82±0.89 
5 39.59±2.50 37.32±0.28 35.76±1.78 32.91±0.65 30.48±0.68 
5.5 43.85±2.42 41.51±1.9 38.58±1.63 35.81±0.59 33.59±0.68 
6 49.56±2.26 44.82±2.12 42.77±0.94 39.34±0.75 39.51±0.29 
6.5 52.48±2.57 46.76±2.28 46.61±0.79 42.83±0.43 42.6±0.93 
7 55.49±2.92 50.12±1.62 50.52±0.29 46.72±0.42 46.84±0.91 
7.5 59.67±2.30 56.45±1.03 54.12±0.62 50.02±0.17 49.57±0.18 
8 64.32±2.03 61.57±1.40 57.3±0.55 54.4±0.34 53.11±0.35 
8.5 66.93±1.49 65.16±1.28 61.44±0.89 58.85±0.29 57.56±0.51 
9 69.96±1.75 68.45±1.07 65.77±0.48 63.49±0.53 61.53±0.70 
9.5 74.54±2.09 73.08±1.11 69.16±0.35 68.35±0.67 66.82±0.84 
10 78.75±1.85 76.14±1.29 73.58±0.35 71.43±0.76 70.35±0.80 
10.5 83.64±1.12 80.75±1.83 77.5±0.21 75.68±0.61 73.47±0.69 
11 88.73±0.87 86.32±1.58 82.65±0.62 79.89±1.52 77.46±0.60 
11.5 93.81±0.23 91.92±0.13 87.67±0.91 84.95±1.83 82.78±1.18 
12 96.01±0.34 94.36±0.53 92.09±0.87 89.45±0.69 87.67±0.69 
 
 
 
 
 
 
TABLE 7B INVITRO RELEASE DATA OF OLMESARTAN MEDOXOMIL 
BUCCAL ADHESIVE TABLETS (CARBOPOL: XANTHAN GUM)   (F6-F10) 
Time 
In 
Hours 
 
Cumulative % Drug Release ±SD (n=3*) 
F6(2.5:1) 
(%) 
F7(1.5:1) 
(%) 
F8(1:1) 
(%) 
F9(1:1.5) 
(%) 
F10(1:2.5) 
(%) 
0.25 2.85±0.16 2.47±0.09 2.14±0.18 1.82±0.19 1.49±0.09 
0.5 5.81±0.86 5.7±0.24 4.88±0.24 4.28±0.09 3.35±0.16 
0.75 8.63±0.71 8.08±0.09 7.8±0.16 5.84±0.16 4.79±0.09 
1 11.56±0.25 10.45±0.17 9.48±0.42 8.32±0.16 6.89±0.09 
1.5 14.8±0.86 15.42±0.20 12.63±0.28 11.53±0.21 9.28±0.24 
2 18.49±0.17 18.65±0.33 15.93±0.33 14.82±0.16 12.63±0.31 
2.5 21.59±0.26 21.7±0.43 19.75±0.19 17.14±0.25 14.66±0.26 
3 25.15±0.51 25.04±0.18 22.91±0.33 20.51±0.09 17.56±0.32 
3.5 28.34±0.60 28.34±0.16 26.58±0.41 23.19±0.24 19.51±0.41 
4 31.61±0.59 31.72±0.09 29.29±0.25 26.16±0.24 22.35±0.16 
4.5 35.11±1.07 35.87±0.16 33.17±0.33 29.36±0.09 25.53±0.25 
5 38.53±2.01 39.4±0.24 36.73±0.58 32.96±0.24 29.27±0.10 
5.5 42.94±2.12 43.81±0.16 40.26±0.32 37.07±0.24 32.33±0.19 
6 47.54±1.24 47.6±0.34 45.12±0.41 40.76±0.09 36.6±0.34 
6.5 50.53±1.94 50.75±0.19 47.93±0.31 44.15±0.16 39.42±0.24 
7 54.45±0.54 54.14±0.25 52.22±0.34 46.95±0.24 43.45±0.41 
7.5 57.53±0.82 57.87±0.19 55.84±0.50 49.72±0.33 46.68±0.33 
8 61.82±0.60 60.39±0.33 58.76±0.59 53.2±0.24 49.34±0.34 
8.5 65.43±0.32 65.22±0.66 61.69±0.49 56.71±0.19 52.93±0.34 
9 68.94±0.66 69.77±0.15 65.13±0.60 60.01±0.25 55.62±0.40 
9.5 73.4±0.73 72.05±0.34 69.24±0.30 63.99±0.17 59.13±0.25 
10 77.61±0.84 75.49±0.18 72.83±0.24 67.71±0.19 63.6±0.26 
10.5 81.19±0.46 79.05±0.41 76.38±0.41 72.44±0.08 67.04±0.42 
11 84.78±0.66 83.34±0.19 79.84±0.40 76.31±0.17 71.88±0.28 
11.5 90.79±1.23 87.65±0.32 84.08±0.34 80.43±0.23 76.13±0.24 
12 93.56±0.19 91.44±0.34 88.45±0.32 84.51±0.10 80.68±0.17 
 
 
 
 
 
TABLE 7C INVITRO RELEASE DATA OF OLMESARTAN MEDOXOMIL 
BUCCAL ADHESIVE TABLETS (CARBOPOL: CMC SODIUM)   (F11-F15) 
 
Time 
In 
Hours 
 
Cumulative % Drug Release ±SD (n=3*) 
F11(2.5:1) 
(%) 
F12(1.5:1) 
(%) 
F13(1:1) 
(%) 
F14(1:1.5) 
(%) 
F15(1:2.5) 
(%) 
0.25 2.91±0.09 2.47±0.09 2.09±0.09 1.98±0.09 1.76±0.24 
0.5 5.27±0.24 4.88±0.09 4.55±0.24 4.63±0.49 4.12±0.57 
0.75 7.92±0.19 7.48±0.16 6.88±0.33 6.44±0.24 5.94±0.41 
1 10.55±0.27 9.81±0.16 8.77±0.33 8.5±0.43 7.78±0.34 
1.5 14.35±0.41 13.47±0.24 12.37±0.24 11.43±0.35 10.93±0.24 
2 17.71±0.24 16.76±0.24 15.71±0.52 15.53±0.54 14.27±0.41 
2.5 21.57±0.32 19.75±0.24 19.18±0.16 18.46±0.58 16.97±0.84 
3 24.58±0.32 23.52±0.24 22.62±0.34 20.61±0.75 20.28±0.41 
3.5 28.38±0.24 26.6±0.24 25.31±0.16 23.42±0.51 22.8±0.32 
4 31.64±0.19 30.45±0.24 28.45±0.24 26.4±0.34 25.38±0.49 
4.5 35.8±0.24 34.5±0.33 31.93±0.41 30.2±0.43 28.25±0.25 
5 40.36±0.24 38.84±0.25 35.88±0.24 33.2±0.51 30.8±0.10 
5.5 44.84±0.19 44.12±0.40 40.17±0.41 36.98±0.34 35.06±0.25 
6 49.23±0.25 48.02±0.33 44.7±0.5 40.52±0.34 38.64±0.33 
6.5 52.99±0.29 51.5±0.41 49.2±0.33 44.61±0.43 42.29±0.33 
7 56.34±0.42 55.05±0.24 52.46±0.24 48.18±0.66 46.06±0.49 
7.5 60.84±0.41 58.19±0.25 54.93±0.18 51.66±0.64 49.42±0.35 
8 63.73±0.50 61.94±0.25 57.84±0.18 55.54±0.27 52.75±0.24 
8.5 68.39±0.67 66.03±0.41 62.96±0.32 58.67±0.51 55.81±0.51 
9 71.81±0.34 70.43±0.34 67±0.34 62.42±0.59 60.31±0.32 
9.5 75.57±0.35 73.96±0.50 70.91±0.35 66.63±0.40 64.35±0.25 
10 79.74±0.26 77.08±0.25 74.51±0.32 71.14±0.61 68.07±0.26 
10.5 83.6±0.37 81.42±0.24 79.32±0.50 74.9±0.28 72.14±0.34 
11 87.26±0.43 85.07±0.33 82.74±0.42 79.06±0.44 76.02±0.42 
11.5 91.27±0.34 88.85±0.24 86.62±0.43 83.57±0.44 79.91±0.48 
12 94.14±0.43 92.26±0.24 89.36±0.23 86.96±0.45 83.77±0.77 
 
 
 
 
TABLE 7D INVITRO RELEASE DATA OF OLMESARTAN MEDOXOMIL 
BUCCAL ADHESIVE TABLETS (CARBOPOL: CHITOSAN)   (F16-F20) 
 
Time 
In 
Hours 
 
Cumulative % Drug Release ±SD (n=3*) 
F16(2.5:1) 
(%) 
F17(1.5:1) 
(%) 
F18(1:1) 
(%) 
F19(1:1.5) 
(%) 
F20(1:2.5) 
(%) 
0.25 2.8±0.09 2.47±0.24 1.76±0.18 1.71±0.33 1.49±0.33 
0.5 5.1±0.24 4.72±0.19 4.06±0.24 3.95±0.41 3.08±0.24 
0.75 7.81±0.33 7.1±0.19 6.54±0.24 6.27±0.73 5.56±0.09 
1 10.14±0.33 9.64±0.16 9.04±0.09 8.87±0.25 7.44±0.41 
1.5 14.84±0.24 13.4±0.26 12.72±0.22 11.85±0.32 10.46±0.22 
2 16.99±0.49 16.43±0.49 15.29±0.27 14.88±0.39 13.44±0.24 
2.5 20.64±0.24 19.52±0.16 18.85±0.32 17.96±0.19 16.68±0.32 
3 24.74±0.49 22.69±0.24 21.41±0.28 19.99±0.25 18.25±0.32 
3.5 27.77±0.25 26.09±0.34 23.88±0.19 22.87±0.34 21.68±0.41 
4 30.92±0.33 29.13±0.49 27.61±0.25 25.89±0.33 24.31±0.50 
4.5 35.18±0.28 33.49±0.33 31.26±0.40 28.93±0.25 27.06±0.58 
5 39.2±0.57 37.01±0.93 34.37±0.41 32.8±0.49 30.32±0.34 
5.5 44.16±0.40 42.06±0.43 38.28±0.33 36.03±0.33 34.03±0.41 
6 48.01±0.33 45.41±0.32 42.25±0.41 39.72±0.25 37.17±0.26 
6.5 51.21±0.34 48.71±0.41 45.81±0.50 43.15±0.32 40.42±0.32 
7 54.49±0.34 52.46±0.49 49.06±0.59 46.44±0.66 43.91±0.15 
7.5 57.73±0.57 55.8±0.41 52.92±0.32 50.57±0.42 47.54±0.56 
8 61.48±0.58 59.32±0.40 56.26±0.41 53.9±0.34 51.23±0.49 
8.5 65.35±0.63 62.59±0.19 59.29±0.40 57.24±0.41 54.45±0.58 
9 68.7±0.50 66.14±0.28 62.5±0.74 60.88±0.34 57.75±0.33 
9.5 72.83±0.51 69.76±0.31 66.05±0.53 63.71±0.39 61.11±0.42 
10 77.04±0.34 73.68±0.17 69.46±0.25 67±0.48 64.82±0.24 
10.5 81.05±0.35 77.62±0.23 72.94±0.25 70.57±0.31 68.66±0.42 
11 84.86±0.26 81.52±0.40 76.32±0.96 74.16±0.40 72.45±0.25 
11.5 88.53±0.42 85.39±0.49 80.6±0.75 78.1±0.33 75.84±0.51 
12 92.05±0.48 89.27±0.41 84.35±0.59 80.91±0.59 78.64±0.34 
 
 
 
 
TABLE 7E INVITRO RELEASE DATA OF OLMESARTAN MEDOXOMIL 
BUCCAL ADHESIVE TABLETS (CARBOPOL: CHITOSAN)   (F21-F25) 
 
Time 
In 
Hours 
 
Cumulative % Drug Release ±SD (n=3*) 
F21(2.5:1) 
(%) 
F22(1.5:1) 
(%) 
F23(1:1) 
(%) 
F24(1:1.5) 
(%) 
F25(1:2.5) 
(%) 
0.25 2.8±0.41 2.75±0.19 2.52±0.16 1.98±0.33 1.65±0.18 
0.5 5.65±0.28 4.88±0.24 4.67±0.33 3.63±0.19 3.14±0.33 
0.75 7.81±0.16 7.48±0.16 6.77±0.24 6±0.33 5.01±0.16 
1 10.64±0.33 9.86±0.24 9.1±0.19 8.03±0.41 7.06±0.33 
1.5 13.53±0.24 12.5±0.17 12.59±0.24 11.24±0.22 9.61±0.24 
2 17.16±0.33 16.11±0.41 15.39±0.24 14.55±0.24 12.88±0.09 
2.5 21.18±0.49 19.36±0.28 18.64±0.08 17.9±0.25 16.06±0.25 
3 24.63±0.18 23.23±0.32 22.12±0.24 20.73±0.16 18.79±0.26 
3.5 28.59±0.24 27.13±0.16 25.3±0.32 23.46±0.17 21.93±0.16 
4 31.64±0.41 30.82±0.41 28.61±0.25 26.65±0.25 24.95±0.24 
4.5 35.31±0.24 33.78±0.24 32.21±0.24 29.74±0.25 27.82±0.24 
5 39.37±0.25 37.84±0.24 35.76±0.49 32.91±0.17 30.48±0.24 
5.5 43.79±0.32 40.72±0.24 38.58±0.17 35.81±0.23 33.59±0.25 
6 47.63±0.32 44.76±0.49 42.77±0.25 39.34±0.29 36.51±0.25 
6.5 51.93±0.41 48.55±0.34 46.61±0.25 42.83±0.15 39.6±0.17 
7 55.37±0.32 52.52±0.41 50.52±0.41 46.72±0.50 42.81±0.25 
7.5 58.23±0.24 56.03±0.17 54.12±0.44 50.02±0.34 46.15±0.25 
8 62.15±0.24 59.88±0.41 57.3±0.50 53.4±0.34 49.57±0.25 
8.5 65.76±0.49 63.58±0.26 60.44±0.60 56.85±0.23 53.11±0.25 
9 69.71±0.41 67.09±0.23 63.77±0.54 60.49±0.33 56.56±0.16 
9.5 73.84±0.58 70.88±0.25 67.16±0.51 64.3±0.17 59.53±0.26 
10 77.4±0.33 74.69±0.25 70.58±0.69 67.43±0.16 62.85±0.25 
10.5 81.36±0.25 78.42±0.44 74.5±0.78 70.68±0.25 66.35±0.60 
11 85.45±0.34 82.49±0.42 78.65±0.48 73.89±0.16 70.47±0.31 
11.5 89.34±0.34 86.74±0.26 82.67±0.52 76.95±0.24 73.78±0.18 
12 92.42±0.50 89.87±0.34 87.09±0.43 80.19±0.33 76.68±0.08 
 
 
 
 
TABLE 7F INVITRO RELEASE DATA OF OLMESARTAN MEDOXOMIL 
BUCCAL ADHESIVE TABLETS (HPMC K15M: XANTHAN GUM)   (F26-
F30) 
 
Time 
In 
Hours 
 
Cumulative % Drug Release ±SD (n=3*) 
F26(2.5:1) 
(%) 
F27(1.5:1) 
(%) 
F28(1:1) 
(%) 
F29(1:1.5) 
(%) 
F30(1:2.5) 
(%) 
0.25 2.74±0.24 2.52±0.43 2.36±0.32 2.03±0.16 1.97±0.09 
0.5 5.1±0.18 4.88±0.24 4.61±0.19 4.01±0.16 3.52±0.16 
0.75 7.32±0.33 7.26±0.24 6.82±0.16 6.54±0.24 5.45±0.09 
1 9.49±0.33 9.59±0.25 8.71±0.24 8.65±0.16 7.5±0.16 
1.5 12.97±0.57 12.38±0.24 12.04±0.24 11.6±0.19 10.31±0.14 
2 16.11±0.59 15.61±0.41 15±0.28 14.72±0.25 13.38±0.24 
2.5 19.53±0.34 18.7±0.16 19.39±2.5 17.64±0.41 16.14±0.09 
3 23.24±0.34 21.43±0.17 20.37±0.10 20.47±0.50 19.28±0.41 
3.5 26.53±0.58 24.87±0.66 22.73±0.37 23.25±0.69 21.79±0.28 
4 30.55±0.50 27.63±0.58 25.64±0.25 25.46±0.67 24.47±0.25 
4.5 34.38±0.51 31.93±0.25 28.45±0.26 28±0.73 27.23±0.25 
5 38.11±0.35 34.99±0.24 31.22±0.35 30.61±1.01 29.89±0.33 
5.5 42.2±0.58 38.73±0.29 34.5±0.43 33.06±0.88 32.78±0.41 
6 45.43±0.72 42.22±0.31 37.42±0.59 35.76±0.92 35.3±0.60 
6.5 49.06±0.44 45.01±0.24 40.3±0.52 38.62±0.56 38.01±0.99 
7 52.44±0.44 48.91±0.99 43.41±0.76 41.78±0.44 40.51±1.08 
7.5 56.42±0.28 51.69±0.81 46.53±1.10 45.22±0.28 43.29±0.77 
8 60.33±0.37 54.91±0.68 50.06±1.37 49.01±0.36 46.47±0.62 
8.5 63.93±0.40 58.04±0.51 53.38±1.52 52.49±0.56 49.77±0.55 
9 66.67±0.42 61.68±0.30 56.83±1.28 50.15±0.79 53.15±0.71 
9.5 69.8±0.34 65.06±0.26 60.25±0.88 59.043±0.33 56.16±0.61 
10 72.58±0.23 68.41±0.29 63.73±0.64 62.25±0.35 59.19±0.53 
10.5 75.85±0.39 71.61±0.25 67.51±0.47 65.85±0.42 62.23±0.62 
11 79.42±0.20 75.1±0.25 71.3±0.31 69.31±0.42 65.61±0.54 
11.5 82.51±0.29 78.66±0.25 75±0.15 72.51±0.44 69.07±0.66 
12 85.34±0.51 82.07±0.24 78.45±0.26 75.3±0.25 72.60±0.46 
 
 
TABLE 8A KINETIC STUDIES FOR OLMESARTAN MEDOXOMIL 
BUCCAL ADHESIVE TABLETS 
 
 
 
 
 
FORMULATION 
CODE 
 
ZERO 
ORDER 
 
FIRST 
ORDER 
 
HIGUCHI 
MODEL 
HIXON – 
CROWELL 
MODEL 
KORS-
MEYER & 
PEPPAS 
MODEL 
R
2
 
K0 
h
-1
 
R
2
 
K1 
h
-1
 
R
2
 
KH 
h
1/2
 
R
2
 
KHC 
h
1/3
 
R
2 
 
n 
F1 0.999 7.387 0.836 -0.09 0.954 32.37 0.929 
-
0.222 
0.996 0.928 
F2 0.998 7.916 0.849 
-
0.082 
0.943 31.79 0.941 
-
0.198 
0.99 0.938 
F3 0.997 7.378 0.87 
-
0.072 
0.946 30.09 0.938 -0.19 0.997 0.919 
F4 0.998 7.539 0.884 
-
0.066 
0.937 29.35 0.939 
-
0.179 
0.997 0.968 
F5 0.995 7.133 0.898 
-
0.063 
0.937 29.1 0.947 
-
0.173 
0.997 1.018 
F6 0.998 7.539 0.874 
-
0.079 
0.958 30.77 0.945 
-
0.202 
0.996 0.868 
F7 0.999 7.387 0.909 
-
0.073 
0.967 30.25 0.963 
-
0.192 
0.997 0.887 
F8 0.999 7.539 0.924 
-
0.066 
0.962 29.38 0.967 
-
0.178 
0.997 0.917 
F9 0.998 6.817 0.923 
-
0.058 
0.95 27.85 0.961 
-
0.162 
0.997 0.95 
F10 0.995 6.506 0.925 
-
0.051 
0.938 26.54 0.959 
-
0.148 
0.997 1 
F11 0.999 7.795 0.889 
-
0.084 
0.963 31.92 0.955 
-
0.213 
0.998 0.897 
F12 0.999 7.646 0.906 
-
0.078 
0.962 31.33 0.961 
-
0.202 
0.998 0.923 
F13 0.999 7.418 0.913 -0.07 0.955 30.35 0.96 
-
0.189 
0.998 0.945 
F14 0.997 7.072 0.91 
-
0.063 
0.946 28.84 0.955 
-
0.173 
0.996 0.938 
F15 0.997 6.813 0.923 
-
0.057 
0.944 27.79 0.96 
-
0.161 
0.997 0.957 
TABLE 8B KINETIC STUDIES FOR OLMESARTAN MEDOXOMIL 
BUCCAL ADHESIVE TABLETS 
FORMULATION 
CODE 
 
ZERO 
ORDER 
 
FIRST 
ORDER 
 
HIGUCHI 
MODEL 
HIXON – 
CROWELL 
MODEL 
KORS-
MEYER & 
PEPPAS 
MODEL 
R
2
 K0h
-1
 R
2
 K1h
-1
 R
2
 KHh
1/2
 R
2
 KHCh
1/3
 
R
2 
 
n 
F16 0.999 7.53 0.903 
-
0.076 
0.963 30.83 0.959 -0.198 0.998 0.894 
F17 0.999 7.283 0.919 
-
0.068 
0.961 29.82 0.965 -0.184 0.998 0.913 
F18 0.999 6.887 0.941 
-
0.059 
0.961 28.2 0.973 -0.164 0.996 0.949 
F19 0.998 6.661 0.948 
-
0.054 
0.956 27.24 0.975 -0.155 0.996 0.948 
F20 0.998 6.502 0.946 
-
0.051 
0.949 26.58 0.972 -0.148 0.997 0.991 
F21 0.999 7.587 0.901 
-
0.078 
0.963 31.06 0.959 -0.201 0.998 0.89 
F22 0.999 7.364 0.913 -0.07 0.96 30.13 0.962 -0.188 0.998 0.901 
F23 0.999 7.041 0.925 
-
0.062 
0.959 28.8 0.966 -0.172 0.998 0.908 
F24 0.999 6.638 0.953 
-
0.054 
0.959 27.18 0.978 -0.153 0.998 0.948 
F25 0.999 6.313 0.953 
-
0.048 
0.954 25.84 0.976 -0.141 0.999 0.982 
F26 0.998 7.114 0.955 
-
0.063 
0.97 29.21 0.983 -0.174 0.999 0.893 
F27 0.999 6.683 0.951 
-
0.055 
0.963 27.35 0.979 -0.157 0.998 0.883 
F28 0.997 6.254 0.942 
-
0.049 
0.951 25.45 0.972 -0.148 0.996 0.875 
F29 0.997 6.083 0.952 
-
0.046 
0.953 24.82 0.971 -0.134 0.996 0.896 
F30 0.998 5.838 0.962 
-
0.042 
0.958 23.88 0.981 -0.126 0.999 0.921 
TABLE 9. STABILITY STUDY (40
0
C/75% RH) OF BEST FORMULATION (F1)                       
CARBOPOL 934P:HPMC K15M (2.5:1) 
 
S. No Parameters 
Intervals of testing 
At 0 days At 30 days At 60 days 
1 Physical appearance 
White colour, flat 
shaped 
White colour, flat 
shaped 
White colour, flat 
shaped 
2 Hardness (kg/cm2) 7.0 7.0 7.0 
3 Thickness (mm) 2.4 2.4 2.4 
4 Drug content (%) 99.3 98.8 98.69 
5 Mucoadhesive strength(g) 31.8 31.5 31.5 
6 Surface pH 6.67 6.69 6.76 
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FIGURE 2a: CALIBRATION OF OLMESARTAN MEDOXOMIL  
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FIGURE 2b: DETERMINATION OF ʎ MAX OF OLMESARTAN MEDOXOMIL 
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FIGURE 3a: FTIR SPECTRUM OF OLMESARTAN 
 
 
 
 
FIGURE 3b: FTIR SPECTRUM OF  CARBOPOL 934P 
 
 
 
 
FIGURE 3c: FTIR SPECTRUM OF HPMC K15M 
 
 
 
 
FIGURE 3d: FTIR SPECTRUM OF CHITOSAN 
 
 
 
 
FIGURE 3e: FTIR SPECTRUM OF CMC SODIUM 
 
 
 
 
FIGURE 3f:FTIR SPECTRUM OF XANTHAN GUM 
 
 
 
 
FIGURE 3g: FTIR SPECTRUM OF OLMESARTAN, CARBOPOL 934P AND 
CMC SODIUM 
 
 
 
 
FIGURE 3h: FTIR SPECTRUM OF OLMESARTAN, CARBOPOL 934P AND 
CHITOSAN 
 
 
 
 FIGURE 3i: FTIR SPECTRUM OF OLMESARTAN, CARBOPOL 934P AND 
HPMC K15M 
 
 
 
 
FIGURE 3j: FTIR SPECTRUM OF OLMESARTAN, CMC SODIUM AND 
HPMC K15M 
 
 
FIGURE 3k:FTIR SPECTRUM OF OLMESARTAN, CARBOPOL 934P AND 
XANTHAN GUM 
 
 
 
 
FIGURE 3l: FTIR SPECTRUM OF BEST FORMULATION (F1) 
 
 
 
 
FIGURE 3m: DSC THERMOGRAM OF OLMESARTAN 
 
 
FIGURE 3n: DSC THERMOGRAM OF  CARBOPOL 934P 
 
 
 
 
FIGURE 3p: DSC THERMOGRAM OF CHITOSAN 
 
 
 
FIGURE 3q: DSC THERMOGRAM OF HPMC K15M 
 
 
 
FIGURE 3r: DSC THERMOGRAM OF CMC SODIUM 
 
 
 
FIGURE 3s: DSC THERMOGRAM OF XANTHAN GUM 
 
 
FIGURE 3t: DSC THERMOGRAM OF BEST FORMULATION (F1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4: BULK DENSITY OF ALL THE FORMULATIONS 
 
 
 
FIGURE 5: TAPPED DENSITY OF ALL THE FORMULATIONS 
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FIGURE 6: CARR’S INDEX OF ALL THE FORMULATIONS 
 
 
 
FIGURE 7: HAUSNER RATIO OF ALL THE FORMULATIONS 
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FIGURE 8: ANGLE OF REPOSE OF ALL THE FORMULATIONS 
 
 
 
FIGURE 9a:MUCOADHESIVE STRENGTH OF BUCCAL ADHESIVE 
TABLETS(F1-F5) 
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FIGURE 9b: MUCOADHESIVE STRENGTH OF BUCCAL ADHESIVE 
TABLETS (F6-F10) 
 
 
 
FIGURE 9c: MUCOADHESIVE STRENGTH OF BUCCAL ADHESIVE 
TABLETS    (F11-F15) 
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FIGURE 9d: MUCOADHESIVE STRENGTH OF BUCCAL ADHESIVE 
TABLETS    (F16-F20) 
 
 
 
FIGURE 9e: MUCOADHESIVE STRENGTH OF BUCCAL ADHESIVE 
TABLETS    (F21-F25) 
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FIGURE 9f: MUCOADHESIVE STRENGTH OF BUCCAL ADHESIVE 
TABLETS     (F26-F30) 
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FIGURE 10a: SWELLING INDEX OF BUCCAL ADHESIVE TABLETS            
(F1-F5) 
 
 
 
FIGURE 10b: SWELLING INDEX OF BUCCAL ADHESIVE TABLETS            
(F6-F10) 
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FIGURE 10c: SWELLING INDEX OF BUCCAL ADHESIVE TABLETS     
(F11-F15) 
 
 
 
FIGURE 10d: SWELLING INDEX OF BUCCAL ADHESIVE TABLETS    
(F16-F20) 
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FIGURE 10e: SWELLING INDEX OF BUCCAL ADHESIVE TABLETS  
(F21-F25) 
 
 
 
FIGURE 10f: SWELLING INDEX OF BUCCAL ADHESIVE TABLETS         
(F26-F30) 
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FIGURE 11a: INVITRO DISSOLUTION STUDIES OF OLMESARTAN 
BUCCAL ADHESIVE TABLETS (CARBOPOL: HPMC K15M) 
 
 
 
FIGURE 11b: INVITRO DISSOLUTION STUDIES OF OLMESARTAN 
BUCCAL ADHESIVE TABLETS (Carbopol934: Xanthan Gum) 
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FIGURE 11c: INVITRO DISSOLUTION STUDIES OF OLMESARTAN 
BUCCAL ADHESIVE TABLETS(CARBOPOL:CMC SODIUM) 
 
 
 
FIGURE 11d: INVITRO DISSOLUTION STUDIES OF OLMESARTAN 
BUCCAL ADHESIVE TABLETS(CARBOPOL:CHITOSAN) 
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FIGURE 11e: INVITRO DISSOLUTION STUDIES OF OLMESARTAN 
BUCCAL ADHESIVE TABLETS (HPMC K15M: CMC SODIUM) 
 
 
 
FIGURE 11f: INVITRO DISSOLUTION STUDIES OF OLMESARTAN 
BUCCAL ADHESIVE TABLETS(HPMC K15M:XANTHAN GUM) 
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FIGURE 12a: COMPARISON OF ZERO ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING CARBOPOL AND HPMC K15M IN 
DIFFERENT RATIOS 
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FIGURE 12b: COMPARISON OF ZERO ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING CARBOPOL AND XANTAHN GUM IN 
DIFFERENT RATIOS 
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FIGURE 12C: COMPARISON OF ZERO ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING  CARBOPOL AND CMC SODIUM IN 
DIFFERENT RATIOS 
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FIGURE 12d: COMPARISON OF ZERO ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING  CARBOPOL AND CHITOSAN IN 
DIFFERENT RATIOS 
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FIGURE 12e: COMPARISON OF ZERO ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING HPMC K15M AND CMC SODIUM IN 
DIFFERENT RATIOS 
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FIGURE 12f: COMPARISON OF ZERO ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING  HPMC K15M AND XANTHAN GUM IN 
DIFFERENT RATIOS 
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FIGURE 13a: COMPARISON OF FIRST ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING  CARBOPOL AND HPMC K15M IN 
DIFFERENT RATIOS 
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FIGURE 13b: COMPARISON OF FIRST ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING  CARBOPOL AND XANTHAN GUM IN 
DIFFERENT RATIOS 
0 5 10 15
0.0
0.5
1.0
1.5
2.0
2.5
F6
F7
F8
F9
F10
TIME IN HOURS
L
O
G
 C
U
M
.%
 D
R
U
G
 R
E
L
E
A
S
E
 
 
FIGURE 13c: COMPARISON OF FIRST ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING  CARBOPOL AND CMC SODIUM IN 
DIFFERENT RATIOS 
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FIGURE 13d: COMPARISON OF FIRST ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING  CARBOPOL AND CHITOSAN IN 
DIFFERENT RATIOS 
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FIGURE 13e: COMPARISON OF FIRST ORDER RELEASE KINETICS OF 
FORMULATION CONTAINING HPMC K15M AND CMC SODIUM IN 
DIFFERENT RATIOS 
0 5 10 15
0.0
0.5
1.0
1.5
2.0
2.5
F21
F22
F23
F24
F25
TIME IN HOURS
L
O
G
 C
U
M
.%
 D
R
U
G
 R
E
L
E
A
S
E
 
 
FIGURE 13f: COMPARISON OF FIRST ORDER RELEASE KINETICS OF 
FORMULATION CONTANING HPMC K15M AND XANTHAN GUM IN 
DIFFERENT RATIOS 
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FIGURE 14a: COMPARISON OF HIGUCHI MODEL RELEASE KINETICS 
OF FORMULATION CONTAINING CARBOPOL AND HPMC K15M IN 
DIFFERENT RATIOS 
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FIGURE 14B: COMPARISON OF HIGUCHI MODEL RELEASE KINETICS 
OF FORMULATION CONTAINING CARBOPOL AND XANTHAN GUM IN 
DIFFERENT RATIOS 
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FIGURE 14c: COMPARISON OF HIGUCHI MODEL RELEASE KINETICS 
OF FORMULATION CONTAINING CARBOPOL AND CMC SODIUM IN 
DIFFERENT RATIOS 
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FIGURE 14d: COMPARISON OF HIGUCHI MODEL RELEASE KINETICS 
OF FORMULATION CONTAINING CARBOPOL AND CHITOSAN IN 
DIFFERENT RATIOS 
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FIGURE 14e: COMPARISON OF HIGUCHI MODEL RELEASE KINETICS 
OF FORMULATION CONTAINING HPMC K15M AND CMC SODIUM IN 
DIFFERENT RATIOS 
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FIGURE 14f: COMPARISON OF HIGUCHI MODEL RELEASE KINETICS 
OF FORMULATION CONTAINING HPMC K15M AND XANTHAN GUM 
IN DIFFERENT RATIOS 
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FIGURE 15a: COMPARISON OF HIXSON-CROWELL MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING CARBOPOL AND HPMC 
K15M IN DIFFERENT RATIOS 
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FIGURE 15b: COMPARISON OF HIXSON-CROWELL MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING CARBOPOL AND 
XANTHAN GUM IN DIFFERENT RATIOS 
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FIGURE 15c: COMPARISON OF HIXSON-CROWELL MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING CARBOPOL AND CMC 
SODIUM IN DIFFERENT RATIOS 
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FIGURE 15d: COMPARISON OF HIXSON-CROWELL MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING CARBOPOL AND 
CHITOSAN IN DIFFERENT RATIOS 
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FIGURE 15e: COMPARISON OF HIXSON-CROWELL MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING HPMC K15M AND CMC 
SODIUM IN DIFFERENT RATIOS 
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FIGURE 15f: COMPARISON OF HIXSON-CROWELL MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING HPMC K15M AND 
XANTHAN GUM IN DIFFERENT RATIOS 
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FIGURE 16a: COMPARISON OF KORSMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING CARBOPOL 
AND HPMC K15M IN DIFFERENT RATIOS 
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FIGURE 16c: COMPARISON OF KORSMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING CARBOPOL 
AND CMC SODIUM IN DIFFERENT RATIOS 
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FIGURE 16d: COMPARISON OF KORSMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING CARBOPOL 
AND CHITOSAN IN DIFFERENT RATIOS 
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FIGURE 16e: COMPARISON OF KORSMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING HPMC K15M 
AND CMC SODIUM IN DIFFERENT RATIOS 
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FIGURE 16f: COMPARISON OF KORSMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING HPMC K15M 
AND XANTHAN GUM IN DIFFERENT RATIOS 
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CHAPTER XI 
SUMMARY AND CONCLUSION 
 The objective of the present investigation was to develop olmesartan buccal 
adhesive tablet to achieve controlled release and improve the bioavailability, 
by retarding its extensive hepatic first pass metabolism. 
 FTIR studies indicated that there was no interaction between drug and 
excipients. 
 Buccal adhesive tablets were prepared by direct compression method by 
using different ratios of hydrophilic polymers such as carbopol 934P, HPMC 
K15M, CMC sodium, xanthan gum and chotosan. 
 The formulated tablets were evaluated for pre compression & post 
compression parameters viz mucoadhesive strength, in vitro drug release, 
swelling index, surface pH, drug release kinetics & stability studies. 
 The pre compression parameter of all the formulations was within the 
required limit that was suitable for formulation of the tablets. 
 The post compression parameters such as hardness, thickness, friability, 
uniformity in weight, drug content & mucoadhesive strength of all the 
formulated tablets were within the acceptable limits. 
 Drug release rate was increased with increasing amount of hydrophilic 
polymer. High water uptake which leads to considerable swelling of polymer 
and causes drug to diffuse out from polymer matrix. Moreover the 
hydrophilic polymers would leach out and hence creates more pores and 
channels for drug to diffuse out from the device. 
 The in vitro release studies revealed that the formulation F1 (Carbapol 934P 
and HPMC K15M in 2.5:1 ratio) was selected as best formulation which had 
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the better controlled release (96.01% in 12 hours) and subjected to further 
studies. 
 The in vitro drug release kinetics studies of all the formulations followed zero 
order kinetics and   Non-Fickian diffusion mechanism. 
 IR studies of best formulation (F1) indicated there was no interaction between 
the drug and excipients. 
 The selected formulation was found to be stable under the storage condition. 
CONCLUSION 
Olmesartan medoxomil buccal adhesive tablets could be formulated using the 
drug and hydrophilic mucoadhesive polymers such as carbopol 934P, HPMC K15M, 
CMC sodium, xanthan gum and chotosan in different ratios. Among all the 
formulations F1 showed satisfactory results for swelling behaviour, mucoadhesive 
strength and maximum drug release profile for 12 hours in a controlled manner. Drug 
release kinetic result reveals that all the formulations follow zero-order kinetics and 
Non-Fickian diffusion mechanism. The olmesartan medoxomil buccal adhesive 
tablets may be a good way to bypass the extensive hepatic first-pass metabolism and 
to improve the bioavailability of olmesartan through buccal mucosa. 
 
  
 
 
 
 
 
 
 
 
 
 
REFERENCES 
                                                                                                               REFERENCES 
 
REFERENCES 
Ananda Reddy. K., Venugopal. K., 2012. Formulation and evaluation of buccal 
tablets of piroxicam. Int. J. Chem. Sci. 10(1), 399-412. 
Bhanja Satyabrata., Elaiah. P., Mohanty Chandran., Murthy K.V.R., 2010. 
Design and in-vitro evaluation of mucoadhesive buccal tablets of perindopril 
prepared by sintering technique. International journal of pharmtech research. Vol.2, 
1810-1823. 
Deelip Derle., Omkar Joshi., Ashish Pawar., Jatin Patel., Amol Jagadale., 2009.  
Formulation and evaluation of buccoadhesive bi-layer tablet of propranolol 
hydrochloride. International journal of pharmacy and pharmaceutical sciences. Vol. 
1, 206-212.I 
Shashikant D., Barhate., Kandarp M. Patel,, Ganeshkumar S. Lokhande., 2011. 
Formulation and evaluation of buccoadhesive tablet of Atenolol.  Der Pharmacia 
Lettre. 3(2), 34-38. 
Ravi Krishna. Y., Madhusudhan Rao., Chinna Reddy.K., Sujatha., 2011. 
Formulation and invitro evaluation of  buccoadhesive tablets of furosemide. 
International journal of drug development & research.  Vol. 3, 351-361. 
Vijaya muthumanikandar., Sudeesh Edavalath., Jerry Heison Robert., Raka 
Mukerghee., Vaneesh., 2011. Development and in- vitro evaluation of 
buccoadhesive tablets of losartan potassium. International journal of drug delivery. 
3, 465-471. 
Muthukumaran. M., Dhachinamoorthi., Chandra sekhar. B., 2012. Fabrication 
and evaluation of sustained release mucoadhesive bilayer tablets containing 
nifedipine. Der pharmacia sinica.3(3), 367-376. 
                                                                                                               REFERENCES 
 
 
Hiremath.JG., Sarfaraz. MD., Hiremath. D., Sarudkar. SA., 2009. Preparation 
and physicochemical characterization of simvastatin loaded mucoadhesive bilayered 
tablet. Indian journal of novel drug delivery.1(1), 18-24. 
Gaiah Goud. B., Kumara swamy. S., Praveen kumar. V.,2011. Formulation and 
evaluation of bioadhesive buccal tablets of simvastatin. Journal of advanced 
pharmaceutical sciences.Vol.1, 29-39. 
Guda Aditya., Ganesh Kumar Gudas., Manasa Bingi., Subal Debnath., 
Rajesham. V.V., 2010. Design and evaluation of controlled release mucoadhesive 
buccal tablets of lisinopril. International journal of current pharmaceutical research. 
Vol 2, 24-27. 
Manivannan. R., Balasubramaniam. A., Prem Anand. DC., Sandeep. G., 
Rajkumar. N., 2008. Formulation and in-vitro evaluation of mucoadhesive buccal 
tablets of diltiazem hydrochloride. Research J. Pharm and tech. 1(4), 478-480. 
Margret chandira., Palanisamy. P., Jayakar. B., Rajesh Chatakonda., 2009. 
Design and development of controlled release mucoadhesive oral tablet of 
clarithromycin. International journal of pharma recent research. 1(1), 59-66. 
Ranade A.N., Ranpise N.s., Sanap G.S., Kulkarni R.R., 2011. Development and 
in-vitro evaluation of buccal tablet of quinapril hydrochloride. Indian journal of 
pharmaceutical education and research. Vol 45, 364-369. 
Raviteja Achanta., Pujanitheesha Morampudi., Dineshbabu., Vamshikrishna., 
Nagendrarao Kukalakunta., 2013. Development and in-vitro evaluation of 
buccoadhesive bilayer tablets of thiocolchicoside. Mintage journal of pharmaceutical 
and medical science. Vol.2, 41-44. 
 
                                                                                                               REFERENCES 
 
Raghavendra Rao. N.G., Gururaj. S., Kulkarni., 2012. Formulation and 
evaluation of mucoadhesive buccal bilayered tablets of sabutamol. International 
journal of drug development and research. 4(4), 375-384. 
Sellappan Velmurugan., Kiran Kumar., Raghavarapu., 2013. Formulation and 
in-vitro evaluation of glipizide mucoadhesive buccal tablets. International journal of 
pharma and bio science. 4(2), 594-607. 
Satyabrata Bhanja. C., Zukiuddin Shafeeque. M.D., Muvvala Sudhakar., 2013. 
Mucoadhesive buccal tablets of glimipride- formulation and evaluation. International 
journal of pharmacy and pharmaceutical sciences. Vol 5, 502-510. 
Satyabrata Bhanja., Ellaiah. P., Sujit Kumar Martha., Pratit Kanchan Sahu., 
Sandip Prasad Tiwari., Bibhuti Bhusan Panigrahi., Debajhoti Das., 2010. 
Formulation and in-vitro evaluation of mucoadhesive buccal tablets of timolol 
maleate. Int J pharma biomed res. 1(4), 129-134. 
Suresh Kumar P., Srikanth. B., Shaji. G., Navaneetha Krishnan. S., Saranya. P., 
2011. Formulation and evaluation of nebivolol mucoadhesive buccal tablets. 
Pharmacologyonline 3, 869-885. 
Shiva Krishna. S., Subhabrata Ray., Thakur R.S., 2006. Formulation and 
evaluation of mucoadhesive dosage form containing rosiglitazone maleate. Pak. J. 
pharm. Sci. Vol. 19(3), 208-213. 
Bhaskar Umarji., Rudragouda Patil., Ravindra Birajdar., Swati Mysore., 
Siddramesh Bilagi., Dhananjay audurti., 2012. Formulation and evaluation of 
mucoadhesive buccal tablets of furosemide. World journal of pharmacy and 
pharmaceutical sciences. Volume 1, 1041-1063. 
 
                                                                                                               REFERENCES 
 
Raviteja Achanta., Chandra. S., parthiban. K.G., Naveen Raja Kande., 
Devareddy Sandeepo., 2012. Development and in-vitro evaluation of buccodhesive 
tablets of losartan potassium. International research journal of pharmacy.  3(9), 277-
281. 
Gaurav kumar., samita Gauri., Aashima Hooda., Sangita Saini., Arun Garg., 
2011. Fabrication and evaluation of flavoured mucoadhesive buccal tablet of caffeine 
as CNS stimulant. International journal of  universal pharmacy and life sciences. 
1(3), 85-97. 
Goswami Dhruba Sankar., Goyal Sandeep., Sharma Rani., Mehta Naveen., Puja 
Kumari., Kunwar S Pramod., 2011. Formulation and evaluation of mucoadhesive 
tablets of famotidine. Journal of pharmaceutical and biomedical sciences. 12(60), 1-
3. 
Shashikant D. Barhate., KAndarp M. Patel., Ganeshkumar.S., Lokhande., 
2011.Formulation and evaluation of buccoadhesive tablets of atenolol. Der 
pharmacia letter. 3(2), 34-38. 
Basawaraj S. Patil., Sandeeep S. Tate., Upendra Kulkarni., Srinivas R. 
Soodam., Prasad A. Vedpathak., 2011. Development and in-vitro evaluation of 
mucoadhesive buccal tablets of tizanidine hydrochloride using natural polymer guar 
gum. International journal of advances in pharmaceutical sciences. Vol. 2(2-3), 189-
198. 
Balamurugan.M., Saravanan VS., Ganesh P., Senthil SP., Hemalatha PV., 
Sudhir Pandya., 2008. Development and in-vitro evaluation of mucoadhesive 
buccal tablets of domperidone. Research J. pharm and Tech. 1(4), 377-380. 
 
                                                                                                               REFERENCES 
 
Appa Rao Potu., Naresh Pujari., Shashidher Burra., Prabhakar Reddy 
Veerareddy., 2012. Formulation and evaluation of buccoadhesive tablets of 
quetiapine fumarate. Brazillian journal of pharmaceutical sciences. Vol. 48, 335-
345. 
John D.Smart.,  1993. Drug delivery using buccal-adhesive systems. Advanced drug 
delivery reviews. Vol.11, 253-270. 
Pankil A. Gandhi., Patel M.R., 2011. A review article on buccal adhesive drug 
delivery system. International journal of pharmaceutical research and development. 
Vol. 3(5), 159-173. 
Thomas P. Johnson., Nazila Salamat-Miller., Montakarn Chittchang., 2005. The 
use of mucoadhesive polymers in buccal drug delivery. Advanced drug delivery 
reviews. 57, 1666-1691. 
Anay R. Patel., Dhagash A Patel., Sharad V. Chaudhry., 2011. Mucoadhesive 
buccal drug delivery system. International journal of pharmacy and life sciences. 
Vol. 2(6),848-856. 
Santanu Roychowdhury., Rajesh Gupta., Sourav Saha., 2011. A review on buccal 
mucoadhesive drug delivery systems. Indo global journal of pharmaceutical 
sciences. Vol. 1, 223-233. 
Vinod KR., Rohit Reddy T., Sandhya S., David Banji., Venkatram Reddy B., 
2012. Critical review on mucoadhesive drug delivery systems. Hygeia. J. D. Med. 
Vol.4(1), 7-28. 
Amit Alexander., Ajazuddin., Swarna., Mukesh Sharma., Tripathi D. K., 2011. 
Polymers and permeation enhancers: specialized components of mucoadhesives. 
Stamford journal of pharmaceutical sciences. Vol. 4(1), 91-95. 
 
                                                                                                               REFERENCES 
 
Punitha S., Girish Y., 2010. Polymers in mucoadhesive buccal drug delivery 
system-A review. Int. J. Res. Pharm. Sci. Vol. 1, 170-186. 
Keiko Tsutsumi., Yasuko obata., Tsuneji Nagai., Thorsteinn Loftsson., Kozo 
Takayama., 2002. Buccal absorption of ergotamine tartrate using the bioadhesive 
tablet system in guinea-pigs. International journal of pharmaceuticals. 238, 161-170. 
Sumitha Singh., Vikas Bali., Kamla Pathak., 2011. Development and validation of 
novel spectrophotometric analytical method for the determination of olmesartan in 
pharmaceutical formulations. International journal of pharmacy and pharmaceutical 
sciences. Vol. 3, 487-490. 
Gil Yosipovitch., Ilana Kaplan., Shlomo Calderon., Michael David., Yiong Huak 
Chan., Abraham Weinberger., 2001. Distribution of mucosal pH on the buccal 
cavity. Acta Derm Venerol. 81, 178-180. 
Ashwini A. Yadav., Dhanashri S Yadav., Poonam S Karekar., Yogesh V Pore., 
Pankaj Gajare., 2012. Enhanced solubility and dissolution rate of olmesartan 
medoxomil using crystallo-co-agglomeration technique. Der Pharmacia Sinica. 3(2), 
160-169. 
Abdullah Al Masud., Mahfuzur Rahman., Moynul Hasan., Kamal Hossain 
Ripon., Ahsanur Rahman., Rabiul Islam., Raihan Sarkar., 2012. Validated 
spectrophotometric method for olmesartan medoxomil in pharmaceutical 
formulation. International journal of pharmaceuticals and life sciences. Vol.1, 1-7. 
Shivanand K., Raju S. A., Jaykar B., 2010.  Mucoadhessive bilayered buccal 
tablets of tizanidine hydrochloride. International journal of pharmTech Research. 
Vol.2, 1861-1869. 
 
                                                                                                               REFERENCES 
 
Ankarao A., Jitendra kumar. P., Babu rao., Devanna. N., Venkata Phani 
Deepthi. B., 2011.  Formulation and evaluation of buccoadhesive bilayered tablets of 
carvedilol. International journal of pharmaceutical, chemical and biological 
sciences. 1(1), 6-11. 
Yadav Deepak R., Ayyappan T., Shanmugam S., Sundaramoorthy K., 
Vetrichelvan T., 2011.  Development and in-vitro evaluation of buccoadhesive 
metoclopramide hydrochloride tablet formulations. International journal of 
pharmTech research. Vol. 3, 516-525. 
Gururaj. S Kulkarni., Raghavendra Rao N. G., Narasimhareddy D., 2013. 
Formulation development and evaluation of terbutaline sulphate mucoadhesive 
buccal tablets. Int. Res. J. Pharm. 4(3), 189-192. 
Muthadi Radhika., Vamshi Raj., Reddy M.V.R., 2013. Formulation and in-vitro 
evaluation of buccoadhesive bilayer tablets of enalapril maleate. IJIPSR. 1(1), 96-
108. 
 Vamsi Krishna Murthy G., Narasimharao B.V., Gayathridevi K., Pavani G., 
Harikrishna., 2013. Formulation and evaluation of carvedilol bilayered buccal 
adhesive tablets by direct compression technique. International journal of pharmacy 
and pharmaceutical science research. 3(2), 61-66. 
Raut D.B., Sakhare R.S., Kankudte A.D., Muli P.N., Bharkad V.B., 2013. 
Formulation and in vitro evaluation of mucoadhesive buccal tablet of losartan 
potassium using synthetic 
and natural polymers. World journal of pharmaceutical research. Vol. 2, 1577-1590. 
Praveen.G., 2012. Development and in vitro evaluation of buccoadhesive 
tablets of losartan potassium. The pharma innovation. Vol.1, 63-70. 
 
                                                                                                               REFERENCES 
 
 
 Muthukumaran. M., Dhachinamoorthi. D., Chandra Sekhar. K.B., 2013. 
Development and optimization of hydralazine HCl sustained release mucoadhesive 
buccal tablets using 2
3
factorial design. Int J Adv Pharm Gen Res. 1(2), 20-32. 
 
